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In the name of Allah, Most Gracious, Most Merciful.
﴿              ﴾
6. He it is who shapes you In the wombs As He pleases. there is no god but He, the 
Exalted In Might, the wise.
 ةرﻮﺳآﻥﺍﺮﻤﻋ ﻝ .ﺔﻳﺁ :6  
Aya : 6.Ali 'Imran                  
                
                    
        
6. He created you (all) from a single person: then created, of like nature, His mate; 
and He sent down for you eight head of cattle In pairs: He makes you, In the wombs of 
your mothers, In stages, one after another, In three veils of darkness. such is Allah, 
your Lord and Cherisher: to Him belongs (all) Dominion. there is no god but He: then 
How are ye turned away (from your true Centre)?
 ﺓﺭﻮﺳﺮﻣﺰﻟﺍ .ﺔﻳﺁ :6
Az Zumar. Aya: 6
                          
                         
            
12. Man we did create from a quintessence (of clay);
13. Then we placed Him As (A drop of) sperm In a place of rest, firmly fixed;
14. Then we made the sperm into a clot of congealed blood; then of that clot we 
made a (foetus) lump; then we made out of that lump bones and clothed the bones 
with flesh; then we developed out of it another creature. so Blessed be Allah, the best 
to create!
 ﺓﺭﻮﺳﻥﻮﻨﻣﺆﻤﻟﺍ .ﺔﻳﺁ :12-14
Al Mu'minuun. Aya: 12 - 14
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Abstract
A study was carried out at Omdurman Maternity Hospital, during 
September 3rd to October 10th, to study the protective antibody level of TT 
immunization in pregnant women and their newborns against tetanus using an in 
house ELISA. Two hundred mother-baby pairs were included in this study. 
Mother age, parity, number of pregnancies and doses of TT received before and 
during pregnancy and malaria infections were recorded. Mothers were divided 
into groups according to age, area of residence, level of education and ethnic 
group.
Paired blood samples from each mother and the cord blood of her 
newborn was collected and sera were separated. An in-house ELISA was 
elaborated to measure the protective anti-tetanus antibody level in sera of 
pregnant women and their newborns. Reference anti-tetanus serum dilutions 
were run with test samples as a positive control. Standard curve was generated, 
and the values (IU/ml) of serum sample were obtained by interpolation.
The antibody level in all TT vaccinated women and their newborns were 
above the threshold level needed for protection. The mean mothers TT antibody 
titre was 0.923 and their newborns titre was 1.438 ± 1.82 which is statistically 
significant and there was statistically positive correlation between maternal and 
neonatal antibody titre. About 34.5% of pregnant women and 33.5% of their 
newborn had full protective TT antibody (≥ 1.0 IU/ml), whereas 63% of 
pregnant women and their newborn had a minimum protective antibody ranging 
from ≥ 0.1 to 0.9 IU per ml. Tetanus toxoid antibody level was < 0.1 IU/ml, 
below the protective antibody in 2.5% of pregnant women and their newborn 
and had the risk of contracting tetanus. All age groups had full protective TT 
antibody titre. 
Women who received 3-5 doses of TT vaccine had high mean of TT 
antibody level (1.79 IU/ml) in comparison to those who received 1-2 doses. In 
contrast, women received ≥ 5 doses of TT vaccine had a relatively lower TT 
iv
antibody 0.43 IU/ml. Nonetheless the number of TT doses received by mothers 
had no significant effect on newborn-maternal TT antibody ratio. 
Mother parity had a significantly higher mean of TT antibody level in 
multipari women (1.28 IU/ml) than in primipari women (0.28 IU/ml). Moreover 
there was no significant differences between maternal TT antibodies of malaria 
infected mothers and malaria non-infected mothers. However, the placental 
malaria infection reduced placental transfer of TT antibody from infected 
mothers to their newborn to the level of 0.49 IU/ml compared to 1.56 IU/ml in 
newborn of malaria non-infected mothers. 
Furthermore, place of residence and ethnic group have no effect on TT 
antibody ratio. Although all delivers in this study occurred in hospital setting 
under sterile conditions no baby of the non-vaccinated women or babies of 
women with low TT antibody level had contracted neonatal tetanus.
We believed that WHO immunization schedule is adequate and 
satisfactory to induce a protective TT antibody levels but need to be intensified 
to reach all women of childbearing age.   
vاﻟﻤﺴﺘﺨﻠﺺ
أﻛﺘﻮﺑﺮ 01ﺳﺒﺘﻤﺒﺮ وﺣﺘﻰ 3ﻓﻲ اﻟﻔﺘﺮة ﻣﻦ . أم درﻣﺎن–أُﺟﺮﯾﺖ ھﺬه اﻟﺪراﺳﺔ ﻓﻲ ﻣﺴﺘﺸﻔﻰ اﻟﻮﻻدة 
م، ﻟﺪراﺳﺔ اﻟﻤﺴﺘﻮى اﻟﻮاﻗﻲ ﻟﻸﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ ﺿﺪ ﻟﻘﺎح ذﯾﻔﺎن اﻟﻜﺰاز ﻓﻲ اﻟﻨﺴﺎء اﻟﺤﻮاﻣﻞ وﻣﻮاﻟﯿﺪھﻢ 7002
ﻣﺌﺘﺎ إﻣﺮأة وﻣﻮﻟﻮدھﺎ، وُﺳﺠﱢ ﻠﺖ ﺷﻤﻠﺖ اﻟﺪراﺳﺔ . وذﻟﻚ ﻋﻦ طﺮﯾﻖ إﺳﺘﻌﻤﺎل ﺗﻘﻨﯿﺔ اﻹﻟﯿﺰا اﻟﻤﺤﻠﯿﺔ اﻟﻤﻄﻮرة
ﺑﯿﺎﻧﺎت ﻋﻦ ُﻋﻤﺮ اﻷم، وﻋﺪد اﻟﻮﻻدات، وﻋﺪد ﻣﺮات اﻟﺤﻤﻞ، وﻋﺪد ُﺟﺮﻋﺎت ﻟﻘﺎح ذﯾﻔﺎن اﻟﻜﺰاز ﻗﺒﻞ وأﺛﻨﺎء 
وﻗُﺴﻤﺖ اﻷﻣﮭﺎت إﻟﻰ ﻣﺠﻤﻮﻋﺎت ﺑﻨﺎء ﻋﻠﻰ اﻟﻌﻤﺮ، وﻣﻨﻄﻘﺔ اﻟﺴﻜﻦ، واﻟﻤﺴﺘﻮى .  اﻟﺤﻤﻞ، وإﺻﺎﺑﺎت اﻟﻤﻼرﯾﺎ
  .اﻟﺘﻌﻠﯿﻤﻲ واﻟﻤﺠﻤﻮﻋﺔ اﻟﻌﺮﻗﯿﺔ
أُﺳﺘﺨﺪﻣﺖ . دﻣﺎء ﻣﻦ ورﯾﺪ اﻷم وﻣﻦ اﻟﺤﺒﻞ اﻟﺴﺮي ﻟﻠﺠﻨﯿﻦ وﺗﻢ ﻓﺼﻞ اﻟﻤﺼﻞ ﻣﻨﮭﻤﺎُﺟﻤﻌﺖ ﻋﯿﻨﺎت 
. ﺗﻘﻨﯿﺔ اﻹﻟﯿﺰا اﻟﻤﺤﻠﯿﺔ اﻟﻤﻄﻮرة ﻟﻘﯿﺎس ﻣﺴﺘﻮى اﻷﺟﺴﺎم اﻟﻤﻀﺎدة اﻟُﻤَﻤﻨﱢﻌﺔ ﻓﻲ ﻣﺼﻞ دم اﻷﻣﮭﺎت وﻣﻮاﻟﯿﺪھﻢ
. ﻣﺼﻞ ﻣﺮﺟﻌﻲ ﻣﻀﺎد اﻟﻜﺰاز ﻣﻊ اﻟﻌﯿﻨﺎت ﻣﻮﺿﻮع اﻹﺧﺘﺒﺎر ﻛﻨﻘﻄﺔ ﺗﺤﻜﻢ إﯾﺠﺎﺑﯿﺔأﺳﺘﻌﻤﻠﺖ ﺗﺨﻔﯿﻔﺎت ﻣﻦ 
  .اﻹﺳﺘﯿﻔﺎءﺑﻮاﺳﻄﺔ( وﺣﺪة ﻋﺎﻟﻤﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮ)وُﺻِﻤﻢ اﻟﻤﻨﺤﻨﻰ اﻟﻘﯿﺎﺳﻲ واﻟﺤﺼﻮل ﻣﻨﮫ ﻋﻠﻰ ﻗﯿﻢ 
ﻛﺎن ﻣﺴﺘﻮى اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻓﻲ ﻛﻞ اﻷﻣﮭﺎت اﻟﻤﻠﻘﺤﺎت وﻣﻮاﻟﯿﺪھﻢ أﻋﻠﻰ ﻣﻦ ﻣﺴﺘﻮى اﻟﺘﻤﻨﯿﻊ 
وﻣﻮاﻟﯿﺪھﻢ ﻛﺎن 329.0ﻣﺘﻮﺳﻂ ﻗﯿﺎس اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻓﻲ ﻣﺼﻞ اﻷﻣﮭﺎت ﻛﺎن . اﻟﻤﻄﻠﻮب ﻟﻠﺤﻤﺎﯾﺔ
وھﻲ ذات دﻻﻟﺔ إﺣﺼﺎﺋﯿﺔ وھﻨﺎك ﻋﻼﻗﺔ إرﺗﺒﺎط إﺣﺼﺎﺋﻲ ﻣﻮﺟﺒﺔ ﺑﯿﻦ اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ 834.1ﻮﺳﻄﮭﺎ ﻣﺘ
% 5.43ﺣﻮاﻟﻲ . اﻟﻤﻀﺎدة ﻟﻠﻜﺰاز  ﻟﻸﻣﮭﺎت وﻣﻌﺪل اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ اﻟﻤﻀﺎدة ﻟﻠﻜﺰاز  ﻋﻨﺪ اﻟﻤﻮاﻟﯿﺪ اﻟﺠﺪد
أﻋﻠﻰ ﻣﻦ أو )ﺔ ﺗﻤﺎﻣﺎً ﻣﻦ ﻣﻮاﻟﯿﺪھﻢ ﺗﺤﺼﻠﻮا ﻋﻠﻰ ﻧﺴﺒﺔ أﺟﺴﺎم ﻣﻀﺎدة ُﻣَﻤﻨﱢﻌ% 5.33ﻣﻦ اﻟﻨﺴﺎء اﻟﺤﻮاﻣﻞ و 
ﻣﻦ اﻟﻨﺴﺎء اﻟﺤﻮاﻣﻞ وﻣﻮاﻟﯿﺪھﻢ ﺗﺤﺼﻠﻮا ﻋﻠﻰ أدﻧﻰ ﻧﺴﺒﺔ % 36ﺑﯿﻨﻤﺎ ( وﺣﺪة دوﻟﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮ0.1ﯾﺴﺎوي 
ﻣﺴﺘﻮى اﻷﺟﺴﺎم اﻟﻤﻀﺎدة أﻗﻞ . وﺣﺪة دوﻟﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮ9.0إﻟﻰ 1.0أﺟﺴﺎم ﻣﻀﺎدة ُﻣَﻤﻨﱢﻌﺔ ﺗﺘﺮاوح ﻣﺎ ﺑﯿﻦ 
ﻣﻦ اﻟﻨﺴﺎء اﻟﺤﻮاﻣﻞ % 5.2ﺪ اﻷدﻧﻰ اﻟُﻤَﻤﻨﱢﻊ ﻓﻲ ﺣﻮاﻟﻲ وﺣﺪة دوﻟﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮ وھﻮ أﻗﻞ ﻣﻦ اﻟﺤ1.0ﻣﻦ 
ﻛﻞ ﻣﺠﻤﻮﻋﺎت اﻷﻋﻤﺎر ﻛﺎن ﻟﺪﯾﮭﺎ ﻣﻌﺪل أﺟﺴﺎم . وﻣﻮاﻟﯿﺪھﻢ ﻣﻤﺎ ﯾﻌﻨﻲ ﺧﻄﺮ ﺗﻌﺮض ﻟﻺﺻﺎﺑﺔ ﺑﺎﻟﻜﺰاز
  . ﻣﻨﺎﻋﯿﺔ ُﻣَﻤﻨﱢﻊ ﺗﻤﺎﻣﺎً 
ﺟﺮات ﻣﻦ ﻟﻘﺎح ذﯾﻔﺎن اﻟﻜﺰاز ﻟﺪﯾﮭﻢ أﻋﻠﻰ ﻣﺘﻮﺳﻂ ﻣﺴﺘﻮى 5–3ﯾﻌﺘﺒﺮ اﻟﻨﺴﺎء اﻟﻼﺋﻲ ﺗﻠﻘﯿﻦ ﻣﻦ 
ﻋﻠﻰ اﻟﺠﺎﻧﺐ . ﺟﺮﻋﺔ2–1ﻣﻘﺎرﻧﺔ ﺑﺄوﻟﺌﻚ اﻟﻼﺋﻲ ﺗﻠﻘﯿﻦ ﻣﻦ ( وﺣﺪة دوﻟﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮ79.1)ﯿﺔ أﺟﺴﺎم ﻣﻨﺎﻋ
ﺟﺮﻋﺎت أو أﻛﺜﺮ ﻣﻦ ﻟﻘﺎح ذﯾﻔﺎن اﻟﻜﺰاز  ﻛﺎن ﻟﺪﯾﮭﻦ ﻣﺴﺘﻮى أﺟﺴﺎم ﻣﻨﺎﻋﯿﺔ أﻗﻞ 5اﻵﺧﺮ اﻟﻨﺴﺎء اﻟﻼﺋﻲ ﺗﻠﻘﯿﻦ 
اﻷﻣﮭﺎت ﻟﯿﺲ ﻟﺪﯾﮭﺎ أﺛﺮ وﻣﻊ ذﻟﻚ ﻓﺈن ﻋﺪد اﻟﺠﺮﻋﺎت اﻟﺘﻲ أﺧﺬﺗﮭﺎ ( وﺣﺪة دوﻟﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮ34.0)ﻧﺴﺒﯿﺎً 
  . واﺿﺢ ﻋﻠﻰ ﻣﻌﺪل اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ اﻟﻤﻀﺎدة ﻟﻠﻜﺰاز ﻟﻠﻤﻮاﻟﯿﺪ اﻟﺠﺪد
ﻣﻌﺪل اﻟﻮﻻدة ﻓﻲ اﻷم ﻟﺪﯾﮫ ﺗﺄﺛﯿﺮ إﺣﺼﺎﺋﻲ ﻋﺎﻟﻲ ﻋﻠﻰ ﻣﻌﺪﻻت اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ اﻟﻤﻀﺎدة ﻟﻠﻜﺰاز ﻓﻲ 
  . اﻷﻣﮭﺎت ﻣﺘﻌﺪدات اﻟﻮﻻدة ﻋﻦ ﻓﻲ اﻟﻨﺴﺎء اﻟﻼﺋﻲ ﯾﻠﺪن ﻷول ﻣﺮة
iv
ﻣﺴﺘﻮى اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ اﻟﻤﻀﺎدة ﻟﻠﻜﺰاز ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﻨﺴﺎء اﻟﻤﺼﺎﺑﺎت ﻻ ﯾﻮﺟﺪ ﻓﺮق ﻣﻌﻨﻮي ﻓﻲ 
إﺻﺎﺑﺔ اﻟﻤﻼرﯾﺎ اﻟﻤﺸﯿﻤﯿﺔ ﻗﻠﻠﺖ إﻧﺘﻘﺎل اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ اﻟﻤﻀﺎدة ﻟﻠﻜﺰاز . ﺑﺎﻟﻤﻼرﯾﺎ ﻣﻘﺎرﻧﺔ ﺑﻐﯿﺮ اﻟﻤﺼﺎﺑﺎت
وﺣﺪة 65.1)ﻣﻘﺎرﻧﺔ ﺑـ ( وﺣﺪة دوﻟﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮ94.0)ﻋﺒﺮ اﻟﻤﺸﯿﻤﺔ ﻣﻦ اﻷم إﻟﻰ ﺟﻨﯿﻨﮭﺎ إﻟﻰ ﻣﺴﺘﻮى 
ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ ﻣﻜﺎن اﻟﺴﻜﻦ واﻟﻌﺮق . ﻓﻲ اﻟﻤﻮاﻟﯿﺪ ﻣﻦ أﻣﮭﺎت ﻏﯿﺮ ﻣﺼﺎﺑﺎت ﺑﺎﻟﻤﻼرﯾﺎ( ﻟﯿﺔ ﻟﻜﻞ ﻣﻠﯿﻠﯿﺘﺮدو
  .ﻟﯿﺲ ﻟﮫ ﺗﺄﺛﯿﺮ ﻋﻠﻰ ﻣﻌﺪﻻت اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ اﻟﻤﻀﺎدة  ﻟﻠﻜﺰاز
ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ أن ﻛﻞ اﻟﻮﻻدات ﻓﻲ ھﺬه اﻟﺪراﺳﺔ ﺣﺼﻠﺖ ﻓﻲ ﺗﺠﮭﯿﺰات ﻣﺴﺘﺸﻔﻰ ﻓﻲ ظﺮوف ﻣﻌﻘﻤﺔ 
ﻔﺎل ﻏﯿﺮ اﻟﻤﺤﺼﻨﯿﻦ أو اﻟﻨﺴﺎء ذوي ﻣﻌﺪﻻت اﻷﺟﺴﺎم اﻟﻤﻨﺎﻋﯿﺔ اﻟﻤﻀﺎدة ﻟﻠﻜﺰاز ﻟﻢ ﯾﻜﻦ ھﻨﺎﻟﻚ أي ﻣﻦ اﻷط
  .اﻟﻤﻨﺨﻔﻀﺔ، ﺗﻌﺮﺿﻮا ﻟﻺﺻﺎﺑﺔ ﺑﺎﻟﻜﺰاز اﻟﻮﻻدي
ﻧﺤﻦ ﻧﻌﺘﻘﺪ أن أﺛﺮ ﺑﺮﻧﺎﻣﺞ ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﯿﺔ ﻟﻠﺘﻄﻌﯿﻢ ھﻮ ﻛﺎٍف ﻟﺘﺤﻔﯿﺰ أﺟﺴﺎم ﻣﻨﺎﻋﯿﺔ واﻗﯿﺔ 
  .اﻟﺤﻤﻞوﻟﻜﻦ ﯾﺤﺘﺎج ﻟﻠﺘﻜﺜﯿﻒ ﻟﯿﺼﻞ إﻟﻰ ﻛﻞ اﻟﻨﺴﺎء ﻓﻲ ﻋﻤﺮ ( ُﻣَﻤﻨﱢﻌﺔ)
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INTRODUCTION
     Tetanus is a disease of global importance produced by the toxin of 
Clostridium tetani (Cemalettin et al, 2003). Clinical features of tetanus are 
divided into four symptomatic types: generalized tetanus, local tetanus, cephalic 
tetanus, and neonatal tetanus (Bleck et al., 1991). Epidemics of tetanus leading 
to closure of hospital wards and operation theatres continue to occur (Dastur et 
al, 1980). Although its diagnosis is made clinically, the measurement of anti-
tetanus antibodies is of value in assessing the immune status of individuals at 
risk of tetanus infection (Nagachinta et al, 2002)
     Neonatal tetanus (NT) is a major cause of mortality in developing   countries, 
but can be prevented by proper vaccination and antenatal care (Idema et al., 
2002). Worldwide over 450,000 deaths were estimated to occur annually and 
nearly 40,000 mothers die from tetanus infection acquired during delivery 
(WHO, 1999). The World Health Organization (WHO) had adopted the goal of 
eliminating NT worldwide, and a major strategy for its prevention is the 
administration of at least two properly spaced doses of tetanus toxoid (TT) to 
pregnant women in high risk areas to protect passively their newborns at birth 
(WHO, 2001).
     In many parts of Sudan, women are prone to tetanus while giving birth under 
unhygienic delivery conditions and low TT immunization. These conditions put 
both mother and neonates at risk of tetanus. However, pregnant women and their 
neonate can be protected by immunization. Mustafa et al (1996) showed that 
neonatal tetanus was a major cause of neonatal mortality among rural and 
displaced communities in Khartoum North. The estimated neonatal mortality 
rate ranged between 20.0 and 36.0 per 1000 live births per year, and the major 
cause of death was tetanus neonatorum (29% of neonatal deaths). In recent 
years, war, drought, and famine have brought an estimated 1.5 million displaced 
people to establish poor shanty settlements around the National Capital.  
xviii
    Tetanus toxoid is a potent immunogen that induces long lasting immunity in 
humans. Active immunization with tetanus toxoid is remarkably effective and 
safe (Bleck et al, 1991). 
     Tetanus vaccination had a dramatic impact on the incidence of tetanus 
infection in both neonates and adults worldwide (Dietz et al., 1997). Vaccine 
related immunity to tetanus is associated with the production of neutralizing IgG 
antibodies to TT (Cooper et al., 1999).
      The newborn’s capacity to produce antibodies (IgG) is relatively low and 
transplacental transfer of maternal IgG during the second and third trimesters of 
pregnancy forms the basis of passive protection for the neonate's first months of 
life (De Moraes-Pinto& Hart, 1997). This transfer is an active process involving 
Fc receptors on the surface of the  syncytiotrophoblast (FcII, FcIII & hFcRn), 
that may be altered by damage to the placental architecture (Leach et al., 1996).
Maternal vaccination strategies during pregnancy enhanced the level of 
transplacentally acquired maternal IgG protected newborns against neonatal 
tetanus (Englund et al., 1995)
The principle objectives of this study includes: 
1. To assess immunity to tetanus in pregnant women and their newborns.
2. To assess the level of transplacentally acquired maternal IgG antibody in                         
           their newborns (in cord blood).
3. To assess the ratio of umbilical cord antibodies to maternal antibodies       
          level.
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CHAPTER ONE
LITERATURE REVIEW
1. 1 Definitions
1. 1. 1 Tetanus    
Tetanus is an acute toxemic illness caused by Clostridium tetani exotoxins. 
The route of infection is through laceration or break in the integration of the skin. It 
can also complicated burns, puerperal infections, umbilical stump infections 
(tetanus neonatorum), and surgical wounds. Tetanus is an intoxication manifested 
mainly by neuromuscular dysfunction and caused by tetanal exotoxin 
(tetanospasmin), a potent exotoxin elaborated by C. tetani. It begins with tonic 
spasms of the skeletal muscles and is followed by paroxysmal contractions. The 
muscle stiffness involves first the jaw (lockjaw) and neck and later becomes 
generalized. The disease can be prevented by immunization with tetanal toxoid
(Brook, 2008).
1. 2 History of the disease
     Tetanus has been an important disease worldwide for many generations. It is 
described both in the bible and in the writings of ancient Greek and Egyptian 
physicians (Mallick and Winslet, 2004).
     It derives its name from the Greek word ‘tetanos’ meaning ‘contract’ and has 
been known since antiquity, with descriptions appearing in the Edwin Smith 
papyrus of ancient Egypt (ca. 1600 BC), the writings of Aristotle (ca. 400 BC) and 
the Ayurvedic texts of ancient India 400 AD (Thwaites, 2005).
     The ancient recognized the frequent relationship between injuries and the 
subsequent development of fatal muscle spasms. In 1884, Carle and Rattone 
produced tetanus in animals by injecting them with pus from a fatal human case of 
tetanus. In the same year, Nicolaeir produced tetanus in animals by injecting them 
with samples of soil. However, it was Kitasato in 1889, WHO isolated the 
organism from a human case and reported that the toxin could be neutralized by 
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specific antibodies. In 1897, Nocard demonstrated the protective effects of
passively transferred anti-toxin. Passive immunization in humans was used during 
World War I. Tetanus Toxoid was developed by Descombey in 1924 and the 
effectiveness of active immunization was demonstrated in World War II (Mallick 
and Winslet, 2004).
1. 3 Classification of Clostridium tetani
Clostridium belong to the genus Bacillaceae, endospore forming group 
(Sneath et al., 1986). 
1. 4 Antigenic structure and serotyping
     Ten distinct types (I- X) of C. tetani using C. F. T. and agglutination tests 
have been described based on their flagellar (H) antigen; type 6 consists of non-
flagellate strains (Edlich et al., 2003; Al-Fadil, 1990). All these types have one or 
more common somatic antigens (Edlich et al., 2003).         
     Clostridium tetani shares antigens with C. sporogenes, C. botulinum, and C. 
histolyticum (Al-Fadil, 1990).
1. 5 Toxins from C. tetani
       Tetanus neurotoxin (TeNT), also called tetanospasmin, is produced by C. 
tetani and is responsible for all the neurological disorders of tetanus caused by this 
bacterium. Only one toxinotype of TeNT is known, and those bacteria producing 
TeNT display homogeneous bacteriological characteristics that uniformly from C. 
tetani. Some C. tetani strains become non-toxigenic and indistinguishable from the 
toxigenic strains by phenotype and DNA/ DNA homology. Toxogenic C. tetani
strains contain a lage plasmid (74 kbp) harboring the tent gene (Brüggemann et al., 
2003).   
       Clostridium tetani also produces a chromosomally encoded hemolysin called
tetanolysin O, which belongs to the cholesterol-dependent, pore-forming group of 
toxins. The complete genome sequence of C. tetani has revealed addition virulence 
factors possibly involved in C. tetani invasion into host tissue, which include: (i) 
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two predicted hemolysins; (ii) the ColT collagenase related to Clostridium 
histolyticum collagenases; (iii) a systeine protease related to the clostripain family; 
(iv) two fibronectin- binding proteins; (v) three internalin A homologus, which in 
Listeria mediate their entry into host cells; (vi) six surface layer and/or adhesion 
proteins; and (vii) three membrane proteins related to other bacteria virulence 
proteins. The Colt molecule is plasmid encoded, which genes for the other putative 
factors are located on the chromosome (Poulain et al., 2006)    
1. 6 Epidemiology
1. 6. 1 Introduction
     Tetanus is primarily a disease of unvaccinated individuals and occurs 
wherever public health programmes are poor, thus the majority of cases arise in the 
developing world. Therefore, unlike other infectious diseases, non-immune 
individuals remain vulnerable irrespective of the immune status of the surrounding 
population (Thwaites, 2005).
1. 6. 2 Reservoir of infection
     The natural habitat of the organism is soil and dust. The bacilli are found in 
the intestine of many herbivorous animals, eg., cattle, horses, goats and sheep and 
are excreted in their faeces. The bacilli may be found frequently in the intestine of 
man without causing ill-effects. The spores are blown about in dust and may occur 
in a wide variety of situation including operation theatres (Park, 2005).
1. 6. 3 Environmental and Social Factors
     Tetanus is a positive environmental hazard. Its occurrence depends upon 
man’s physical and ecological surroundings – the soil, agriculture, animal 
husbandly – and not on the presence or absence of infection in the population. The 
environment factors are compounded by social factors such as unhygienic customs 
and habits (e.g., application of dust or animal dung to wounds); unhygienic delivery 
practices (e.g., using unsterilized instruments for cutting the umbilical cord); 
ignorance of infection and lack of primary health care services. In the developed 
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countries, urbanization, industrialization and mechanization of agriculture have 
interfered with the normal process of distribution of C. tetani and have reduced the 
morbidity rate, as has occurred for example in UK, USA and Germany during the 
last 40 years. It is a zonotic disease that affects human and animals. Wound 
contamination with soil or faeces especially in agricultural workers who are 
subjected to injures, in areas where herbivore animals are raised (Park, 2005).
1. 6. 4 Mode of Transmission
     Transmission is primarily through contaminated wounds (Mallick and
Winslet, 2004). The wound may be apparent or inapparent and may be minor or 
major (Cook et al., 2001). In fact, in about 25% of cases in the developed countries, 
the portal of entry is not evident at the time of diagnosis (Cuschieri et al., 2000). 
Tetanus may follow surgery (elective or emergency), burns, puncture wounds, 
crush wounds, otitis media, animal bites, oral infections, child birth and abortion
(Farrar et al., 2000). In intravenous drug users, the potential sources of tetanus 
include contamination of drugs, adulterants (e.g. quinine), paraphernalia and skin.
Tetanus is not however contagious from person to person (Mallick & Winslet, 
2004).
1. 7 Public Health Significance
     The neonatal tetanus was recognised by clinicians during the first 28 days of 
life in resource-poor settings as an important cause of neonatal death. However, 
since babies affected by this disease usually are born at home and die there without 
registration of either event, the true burden was unknown. In the 1970s and 1980s, 
community-based surveys about neonatal tetanus from more than 40 countries 
showed that fewer than 10% of tetanus-related cases and deaths were routinely 
reported in most countries: in some regions, the reporting fraction was as low as 2–
5% (Stanfield and Galazka, 1984; Galazka et al., 2004). Estimates based on the 
results of these surveys, and tetanus data routinely reported to WHO suggested that, 
in the 1980s, more than one million deaths every year were attributable to tetanus, 
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with an estimated 787 000 deaths in 1988 from neonatal tetanus alone. In 1989, the 
worldwide public-health community made a commitment to the elimination of 
neonatal tetanus (defined as fewer than one case of neonatal tetanus per 1000 live 
births in all districts) by 1995 (Roper et al., 2007). Neonatal tetanus is responsible 
for 14% (215,000) of all neonatal deaths as shown in figure 1:1(WHO, 1998).
     Maternal tetanus has the same risk factors and means of prevention as 
neonatal tetanus. In the early 1990s it was estimated to account for about 5% of 
maternal mortality (figure 1: 2), or 15 000–30 000 deaths every year (Fauveau et 
al., 1993; WHO, UNICEF, UNFPA, 2000). In 1999, the elimination of maternal
tetanus was added to the goals of the elimination programme for neonatal tetanus, 
and the initiative was renamed the Maternal and Neonatal Tetanus Elimination 
Program (WHO, UNICEF, UNFPA, 2000).
     Good progress has been made in the 15 years since the neonatal tetanus 
elimination programme began. Worldwide mortality from neonatal tetanus cases 
was estimated as 180 000 in 2002, which represents a 78% reduction since the late 
1980s (Stanfield & Galazka, 1984; WHO, 2006). This disease now accounts for 5–
7% of worldwide neonatal mortality, where it was 14% in 1993 (Vandelar et al., 
2003; Lawn et al., 2004). Estimates of present incidence and mortality of maternal 
tetanus are unavailable; however, the number of deaths worldwide from this 
disease has probably undergone a commensurate reduction (Roper et al., 2007).
     In developed countries, both maternal and neonatal tetanus is now little more 
than a medical curiosity; maternal and neonatal tetanus are exceedingly rare 
(Pascual et al., 2003; Rushdy et al., 2003). However, tetanus as a whole continues 
to cause about 213 000–293 000 deaths worldwide each year, predominantly in 
low-income and middle-income countries. Deaths from maternal or neonatal 
tetanus are concentrated in 48 countries, mostly in Asia and Africa (Roper et al., 
2007).
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Figure 1: 3 Causes of neonatal deaths Figure 1: 4 Causes of obstetrical deaths
Sources: WHO Mother and Baby Package, 1993.
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1. 7. 1 Tetanus in the Sudan
     In the Sudan, as elsewhere, routine reporting systems fail to document the 
true incidence and mortality (SMH, 1981, Olive et al., 1982). The few studies on 
neonatal tetanus in the Sudan indicated that its prevalence is higher in rural areas 
and among certain ethnic and tribal groups, partly because of traditional habits and 
practices regarding care of delivery and attention to the cord, in addition to lack of 
environmental hygiene and public health awareness (Olive et al., 1982, Woodruff, 
1984).
The estimated neonatal mortality rate ranged between 20.0 and 36.0 per 1000 
live births per year, and the major cause of death was tetanus neonatorum (29% of 
neonatal deaths). The mortality rate was lowest when tetanus toxoid was received 
during pregnancy and the umbilical cord was cleaned by a modern hygienic 
method. In contrast, the mortality rate was highest when no tetanus toxoid was 
received and no or traditional cord cleaning was used. Safe deliveries and wider 
immunization coverage are needed to control neonatal tetanus in this community
(Taha et al., 1993).
In recent years, war, drought, and famine have brought an estimated 1.5 
million displaced people to establish poor shanty settlements around the National 
Capital. The neonatal tetanus situation in these populations has not been 
documented. This community- based survey aimed to study the incidence and 
mortality of neonatal tetanus in these and in rural communities; and to assess 
coverage with and attitude towards tetanus toxoid in them (Mustafa et al., 1996).
1. 8 Pathophysiology
     Following introduction into tissues, spores convert to vegetative forms, 
multiply, and elaborate tetanospasmin. In many cases, the disease is not associated
with inflammation or apparent local infection. Tetanospasmin enters the peripheral
nerve at the site of entry and travels to the central nervous system (CNS) through
the nerves or is transferred by the lymphocytes to the CNS. The toxin affects the 
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nervous system centrally and peripherally. The toxin binds to gangliosides at the 
presynaptic nerve ending in the neuronal membrane, prevents release of 
neurotransmitters, and affects polarization of postsynaptic membranes in complex 
polysynaptic reflexes. The lack of inhibitory impulses that result is manifested in 
the characteristic spasms, seizures, and sympathetic overactivity of tetanus. The 
toxin has no effect on the mental status, and consciousness is not impaired directly 
by this illness (Brook, 2008).
     Tetanospasmin also becomes bound to gangliosides within the CNS where it 
suppresses the motor neurons and interneurons without directly enhancing synaptic 
excitatory action. Additional actions of tetanospasmin are evident in the 
neurocirculatory, neuroendocrine, and vegetative nervous systems. Once it binds to 
tissue, toxin cannot be dissociated or neutralized by tetanus antitoxin. Antitoxin 
may prevent binding in the CNS if binding has taken place in the periphery (brook, 
2008).
1. 9 Clinical Manifestations
     Tetanus is characterised by muscle rigidity and painful muscle spasms 
caused by tetanus toxin’s blockade of inhibitory neurons that normally oppose and 
modulate the action of excitatory motor neurons. Maternal and neonatal tetanus are 
both forms of generalised tetanus and have similar courses. The time from 
inoculation of tetanus spores into damaged tissue to the appearance of the first 
symptom, (incubation period) is usually 3–21 days (median 8 days), although cases 
have been reported with incubation periods as short as 1 day, or longer than a 
month. The average incubation period for neonatal tetanus (age at first symptom) is 
shorter than that of non-neonatal tetanus. About 90% of neonates with tetanus 
develop symptoms in the first 3–14 days of life, mostly on days 6–8, distinguishing 
neonatal tetanus from other causes of neonatal mortality which typically occur in 
the first two days of life (Martha et al., 2007).
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1. 9. 1 Clinical course of neonatal tetanus
   Usually occurs as the generalized form and is usually fatal if left untreated.
It develops in children born to inadequately immunized mothers, frequently after 
unsterile treatment of the umbilical cord stump. Its onset generally comes during 
the first 2 weeks of life as shown in figure (1: 3). Failure to suckle is often the first 
sign of infection in the neonate, and typically occurs between the third and tenth 
day of life. In spite of efforts by the infant, spasms of the masseter muscle (upper 
and lower jaw) impede feeding (Figure 1:3a). Trismus (a spasm of the masticatory 
muscles) apparently disturbs the proper movement of the lips that helps control 
sucking. The newborn becomes irritable and cries constantly. The mother may still 
manage to squeeze milk into the mouth or spoon-feed the infant, but the jaw’s 
rigidity impedes swallowing. The cry of the affected newborn varies in intensity 
from a short, hoarse sound to a gurgle. Exhaustion brings about cessation of audible 
crying (PAHO, 2005).
     As a rule, neonatal tetanus follows a descending pattern of nerve 
involvement. The first sign is usually trismus or lockjaw, followed by difficulty 
swallowing, stiffness in the neck, rigidity of abdominal muscles, and a temperature 
rise of 2ºC – 4ºC above normal. Spasms may occur frequently and last for several 
minutes. In the hours following the appearance of the first symptoms, generalized 
rigidity often occurs at the same time as the initiation of spasms. The jaw contracts 
and the lips stretch laterally in an upward direction. The eyebrows are frequently 
arched, and the facial expression is that of a sardonic smile (risus sardonicus). 
Sometimes the lips are pursed as if to whistle (Figure 1: 3b). The interval between 
the first symptoms, usually cessation of suckling or trismus, and the occurrence of 
spasms is called the period of onset. In neonatal tetanus this period is important for 
the prognosis: the shorter the period of onset, the higher the fatality rate. The 
tetanic spasms become more frequent and often are initiated by light or noise. Such 
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Figure 1:3 Neonatal tetanus before and after treatment (PAHO, 2005).
a b
c d
e
Difficulty sucking due to spasms of the 
oral muscles.
First symptoms of widespread rigidity 
and trismus.
Opisthotonos caused by spasms of the 
spinal muscles.
After treatment, the mouth muscles are 
relaxed and child can suckle.
Spasms gradually cease and
generalized rigidity disappears.
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spasms can last from a few seconds to more than a minute. Respiration is affected; 
infants can become pale or cyanotic, and some may die during the attack. The arms 
are usually flexed at the elbow, and the hands may be drawn to the chest during the 
spasm. When the fist is tightly clenched, the thumb often interlocks with the 
fingers. The feet are in dorsiflexion with the toes tightly gripped. This hyperflexion 
of the toes is very characteristic of the level of rigidity and hypertonia of the plantar 
muscle. The neck is arched backwards slightly and the abdominal and dorsal 
muscles are very rigid. Due to spasms of the back muscles, the back is arched 
(Figure 1: 3c). After treatment, spasms gradually subside and eventually disappear 
(Figures 1: 3d & 1: 3e). In half of the newborns with tetanus, infection of the navel 
(omphalitis) is not evident. Extensive infection may cause diffuse inflammation of 
all the anterior abdominal muscles. The child can die of apnea or serious anoxia 
during the spasms, or two to four days later due to acute gastroenteritis or 
complications from difficulty in swallowing that lead to pneumonia (PAHO, 2005).
1. 9. 2 Clinical course of maternal tetanus (non-neonatal)
     Three basic forms may be distinguished: local, cephalic, and generalized 
(Edlich et al., 2003; Mallick and Winslet, 2004).
1. 9. 2. 1 Localized Tetanus
     It is an uncommon form in which manifestations are restricted to muscles 
near the wound. The prognosis is excellent (Abrutyn, 2005). It begins with pain, 
rigidity and muscle spasms of the affected body part. This may be the only
complaint in a patient with a small amount of toxin production or with some 
antibodies able to neutralize circulating toxin. If the toxin is not neutralized, it 
continues its ascending way into the CNS leading to the generalized form of the 
disease (Atriham et al., 2007)
1. 9. 2. 2 Cephalic Tetanus     
     A rare form of local tetanus, follows head injury or ear infection and 
involves one or more facial cranial nerves. The incubation period is a few days and 
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mortality is high (Abrutyn, 2005). Cepahlic tetanus can remain localized or 
progress into the generalized form which has a poor prognosis (Atriham et al., 
2007).  
1. 9. 2. 3 Generalized Tetanus      
     The most common form of the disease is characterized by increased muscle 
tone and generalized spasms. The median time of onset after injury is 7 days; 15% 
of cases occur within 3 days and 10% after 14 days. Typically, the patient first 
notices increased tone in the masseter muscles. Dysphagia or stiffness or pain in the 
neck, shoulder, and back muscles appears concurrently or soon thereafter. The 
subsequent involvement of other muscles produces a rigid abdomen and stiff 
proximal limb muscles; the hands and feet are relatively spared. Sustained 
contraction of the facial muscles results in a grimace or sneer (risus sardonicus), 
and contraction of the back muscles produces an arched back (opisthotonos)
(Abrutyn, 2005) as shown in figure 1: 4). These generalized contractions can be 
strong enough to cause laryngeal obstruction, respiratory muscle paralysis and even 
fractures. The autonomic dysfunction of this stage of the disease also represents a 
significant therapeutic challenge and contributes to the high morbidity and 
mortality. It is characterized by high catecholamine release, as demonstrated by 
profuse sweating, tachycardia, hyperthermia, hypertension, and urinary retention 
(Atriham et al., 2007). 
1. 9. 3 Severity grading
     Several grading systems reported by Ablett is most widely used is classified 
as mild, moderate, severe and very severe as shown in table 1:1(Cook et al., 2001; 
Mallick and Winslet, 2004). 
1. 9. 4 Distribution and risk factors of maternal and neonatal tetanus
      Maternal and neonatal tetanus cases are clustered in poor, remote, and 
disenfranchised communities where unhygienic obstetric and postnatal practices
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Fig 1: 8 This patient is displaying a bodily posture known as "opisthotonos" due to Clostridium 
tetani exotoxin (Generalized tetanus, the most common type (about 80%) usually presents with a 
descending pattern, starting with trismus or lockjaw, followed by stiffness of the neck, difficulty 
in swallowing, and rigidity of abdominal muscles). (CDC, 2007).
Table 1:2 Ablett classification of severity of tetanus (Cook et al., 2001; Mallick and                 
                Winslet, 2004).
Grade Type Signs and symptoms
I Mild mild to moderate trismus; general spasticity; no 
respiratory embarrassment; no spasms; little or no 
dysphagia
II Moderate moderate trismus; well-marked rigidity; mild to moderate 
but short spasms; moderate respiratory embarrassment 
with an increased respiratory rate greater than 30; mild 
dysphagia
III Severe severe trismus; generalized spasticity; reflex prolonged 
spasms; increased respiratory rate greater than 40; apnoeic 
spells; severe dysphagia; tachycardia greater than 120
IV Very 
severe
very severe: grade III plus violent autonomic severe 
disturbances involving the cardiovascular system. Severe 
hypertension and tachycardia alternating with relative 
hypotension and bradycardia, either of which may be 
persistent.
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prevail, and access to maternal tetanus toxoid immunisation is poor (Balmer et al., 
2007). Differences in neonatal tetanus incidence and mortality of at least an order 
of magnitude have been identified between regions and countries, and between 
urban and rural areas within countries (Galazka et al., 2004). In industrialised 
countries, neonatal tetanus ceased to be a substantial problem by the mid-20th 
century: once tetanus toxoid vaccination became widespread, neonatal tetanus 
disappeared (Rushdy, 2003). By contrast, mortality rates as high as 67–110 per 
1000 livebirths were identified in rural populations in developing countries in the 
1960s and 1970s, (Balmer et al., 2007) with neonatal tetanus accounting for 50% or 
more of all neonatal deaths and 25% of infant mortality in some countries (Galazka 
et al., 2004). Although this situation has improved in the past 20 years, neonatal 
tetanus mortality rates of 23 and 82 per 1000 livebirths were detected in remote 
communities in the late 1990s (Quddus et al., 2002; Meegan, 2001) 49 countries 
continue to have neonatal tetanus rates of more than 1 per 1000 live-births in some 
districts (WHO, 2006).
Information about the incidence and distribution of maternal tetanus is based 
on more limited data than that available for neonatal tetanus. Both tetanus and 
maternal mortality are under-reported. Induced abortion is illegal in many 
countries, so resulting tetanus cases and deaths are even less likely to be reported 
than those resulting from childbirth. In studies from several Asian countries from 
the 1950s and 1960s, maternal tetanus accounted for 3–22% of all tetanus cases, 
with an overall average of 7% (Balmer et al., 2007). In a 1993 review of studies 
addressing maternal tetanus, tetanus-associated maternal mortality rates established 
in community-based studies ranged from 4–56 per 100 000 livebirths (Fauveau et 
al., 1993). Tetanus was the cause of 0·2–10% of all maternal deaths, with an 
overall average of about 5%. Of reported cases of maternal tetanus, 27% took place 
after induced abortion (Fauveau et al., 1993). In a subsequent community-based 
study from Bangladesh, where efforts to eliminate neonatal tetanus were underway, 
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Table1:2 Risk factors associated with neonatal and maternal tetanus
(Martha et al., 2007).
Factors associated with unsafe procedures
 Deliveries or medical procedures done outside health-care facilities.
 Birth attendants without medical training
 Unclean hands and instruments
 Dirt, straw, or other unclean materials as delivery surface
 Animals kept inside or adjacent to home (for home deliveries)
 Animal dung used for fuel
 Traditional substances used during labour, delivery, or abortion (ie, cow    
   ghee and other animal or vegetable oils, juices or herbs)
 Traditional substances used for umbilical cord care (ie, cow dung, rat     
  faeces, cow ghee, other oils or juices, herbs, ash, surma, soil, sand)
 Neonates swaddled in animal dung or soil
 Traditional neonatal surgeries (ie, circumcision, ritual scarification, ear 
piercing, uvulectomy)
Immunization-related factors
 Absent or incomplete immunization with tetanus toxoid
Factors associated with unsafe procedures or incomplete immunisation, 
or both
 Poverty
 Absent or poor maternal or paternal education, or both
 Poor antenatal-care attendance 
 Young maternal age or first pregnancy, or both
 Cultural constraints to women’s movements and contacts
Other factors
 Death of a previous child in a family from neonatal tetanus (predictive  
  of subsequent cases)
 Male sex (increased risk of neonatal tetanus)
Specific factors can be related to unsafe delivery, abortion, or cord-care practices,
or to inadequate immunization with tetanus toxoid, or both. 
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1% of deaths in women aged 10–50 years were due to maternal tetanus, of which 
35% were associated with abortion. In a related hospital record review, of women 
aged 10–50 years who died of tetanus, 55% developed tetanus after induced 
abortion and 5% after childbirth (Balmer et al., 2007).
1. 10 Diagnosis of tetanus
     The diagnosis of tetanus is based entirely on clinical findings (Abrutyn, 
2005), rather than on bacteriologic findings (Edlich et al., 2003) because tetanus 
spores are rarely identified at the portal of entry, and tetanus antibody levels are not 
routinely available (Kumar, 2001). The diagnosis of tetanus is relatively easy in 
areas where tetanus is seen often but is delayed in the developed world, where 
cases are seen infrequently (Edlich et al., 2003).
1. 10. 1 Clinical Diagnosis
     In addition to trismus, physical examination may reveal marked 
hypertonicity of the muscles, hyperactive deep tendon reflexes, clear mentation, 
low-grade fever, and absence of sensory involvement. Local or general paroxysmal 
spasms may be observed. The vastmajority of these patients have evidence of a 
wound that occurred within the last 2 weeks. Such patients commonly have no 
clear history of previous tetanus toxoid immunization (Edlich et al., 2003).
1.10. 1. 2 Clinical Differential Diagnosis of neonatal tetanus 
     While no other disease clinically resembles full-blown neonatal tetanus, 
there are a number of medical conditions that can display one or more similar 
clinical characteristics. The differential diagnosis should take into account causes 
of neonatal convulsions. In general, there are three etiologic categories of neonatal 
convulsions:
• Congenital (cerebral anomalies);
• Perinatal (complicated delivery, perinatal trauma and anoxia, or                   
intracranial hemorrhage); and
• Postnatal (infections and metabolic disorders).   
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     Laboratory confirmation of neonatal tetanus is difficult. Isolation of the 
microorganisms can be attempted by inoculation of the umbilical stump material 
onto a suitable culture medium. In most cases, the microorganisms cannot be 
recovered from the site of infection. There are no specific laboratory tests that show 
abnormalities characteristic of tetanus. The diagnosis is clinical and does not 
depend on bacteriologic confirmation (PAHO, 2005).
1. 10. 2 Bacteriologic studies
     The Bacteriologic studies of tetanus involve the isolation and identification 
of C. tetani and the detection of toxigenicity in the isolate by mouse toxicity 
testing. The latter is the definitive test for the Bacteriologic studies of tetanus.
     Bacteriologic studies can confirm the presence of C. tetani in only about 
one-third of all patients who have clinical evidence of the disease. It must also be 
remembered that isolation of C. tetani from contaminated wounds does not mean 
that the patient will contract or has contracted tetanus (Edlich et al., 2003). 
Attempts to culture C. tetani from wounds are not useful in diagnosis, because (1)
even carefully performed anaerobic culture are frequency negative; (2) a positive 
culture does not indicate whether the organism contains the toxin-producing 
plasmid; and (3) a positive culture may be present without disease in patients with 
adequate immunity (Bleck, 1989). 
The frequently isolation of isolation of C. tetani from wounds of patients 
with clinical tetanus may be improved by heating one set of specimens to 80 °C for 
15 minutes to destroy vegetative forms of non-sporulating competing 
microorganisms before culture media are inoculated (Edlich et al., 2003).
1. 10. 2. 1 Isolation and identification of C. tetani
1. 10. 2. 1. 1 Suitable specimens
     Wound swabs in Stuart’s transport medium are the usual clinical specimens 
submitted for the laboratory diagnosis of tetanus. Surgical specimens also suitable 
when collected (PHLN, 2000).
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1. 10. 2. 1. 2 Morphology and Staining:
     C. tetani is a long, thin (2 to 5 µm × 3 to 8 µm) (Wilfert & Hotez, 2003), 
none capsulated (Carden, 2004) an anaerobic, motile, gram-positive rod that forms 
an oval, colorless (Abrutyn, 2005) and readily forms endospores (Edlich et al., 
2003). In gram stain preparations; these bacteria can occur singly in pairs, or in 
long chains (figure 1: 9). The spores in C. tetani are usually broader than the 
vegetative organisms in which they are formed, imparting the characteristic spinder 
or “tennis-racket” morphology. Young culture (< 8h) of C. tetani stain gram 
positive, while older cultures can be readily discolorized with ethanol and often 
appear gram-negative (Dürre, 2005) (figure 1:10), older organisms lose their 
flagella after the development of a spore (Farrar et al., 2000). 
1. 10. 2. 1. 3 Cultural characters
     C. tetani is considered a strict anaerobe that grows optimally at 33 to 37ºC; 
however, depending on the strain, growth can occur at 14 to 43ºC (Wassilak et al.,
1994). Growth on ordinary nutrient media but more readily grown in CMB or in 
fildes peptic blood broth or on fresh blood agar. Colonies on solid media show fine 
branching projections. After incubation for 48-72 h, the central part of the colony
becomes slightly raised and has a ground-glass appearance with a delicately 
filamentous edge (Collee et al., 1996). Under anaerobic conditions the organisms 
are easily isolated on blood agar or lipase and lecithinase activity. Gas liquid 
chromatographic analysis of minor amount of propionic acid is used (PHLN, 2000).
Under anaerobic conditions the organisms are easily isolated on blood agar or in 
cooked meat broth. The organism does not ferment carbohydrates, does not usually 
liquefy gelatin, and produces little change in litmus milk (Wilfert & Hotez, 2003).
Because C. tetani is an obligate anaerobe, after incubation under anaerobic 
conditions at 350C for 24 h, it produces a thin transparent film of swarming growth 
on the agar surface. Blood in blood agar medium is haemolysed. The thin film of 
growth may be difficult to detect (PHLN, 2000).
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Figure 1:9 C. tetani Gram stain. The bacterium is Gram-positive, but like many older cultures of 
clostridia, there is a tendency towards Gram variability. Vegetative cells are relatively large rod-
shaped cells. Endospores are formed intra cellularly at the tips of the sporangium and cause a 
characteristic swelling (Wilfert & Hotez, 2003).
Figure 1: 10 Electron micrograph of Clostridium tetani. Endospores are formed at the tips of the 
cell and they cause the sporangium (cell that contains a spore) to swell, which imparts a 
characteristic "drumstick" appearance to the cells. From (Kumar, 2001)  
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         Biochemically, C. tetani is an asaccharolytic species of Clostridium that 
liquefies gelatin. The species also produces H2S and DNAse but gives negative 
reactions for nitrate reduction, aesculin and starch hydrolysis and metabolic 
products shows a predominance of acetic and butyric acids with a minor amount of 
propionic acid (PHLN, 2000).
1. 10. 2. 2 Mouse testing for tetanus toxin (tetanospasmin)
     Cultures of C. tetani in Cooked Meat Medium (CMM) broth. The 
supernatant broth culture is filtered through a filter of 0.45 mm APD rating and 
small volumes of the filtrate are injected into mice. Broth cultures are tested for 
toxigenicity after incubation at 350C for 18-24 h; and, if negative, are re-tested after 
incubation for up to 4 days. Small mice, preferably of body weight 15-18 g, are 
inoculated intramuscularly in the thigh with 0.1 and 0.3 ml volumes of filtrate. 
Control mice are inoculated intraperitoneally with 0.5 ml (1500 U) of tetanus 
antitoxin 1 h before injection of the filtrate. The tetanus antitoxin will specifically 
neutralize the neurotoxic effects of tetanospasmin. Smaller volumes/lesser amounts 
of tetanus toxin produce stiff paralysis in the leg of the mouse while larger 
volumes/more toxin tends to kill the animal within 18-24 h. These effects are 
prevented by the prior injection of mice with tetanus antitoxin (PHLN, 2000).
1.10. 3 Methods for Measuring Antitoxin
     Although reliable methods of measuring antitoxic neutralizing antibodies 
have existed for many years for tetanus antitoxin, regular clinical laboratories 
rarely maintain the capability of determining tetanus antitoxin levels because they 
are of no use in diagnosis or treatment of acute disease. They are also time-
consuming and are mainly used as research tools. The most reliable method for 
determining tetanus antitoxin levels is in vivo neutralization of toxin which 
depends upon antibodies of the IgG class. The mouse neutralization assay is the 
most widely used. PHA has good correlation with neutralization tests. This detects 
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IgM and IgG antibodies, and since only IgG is active in neutralization tests, low 
levels of early antibodies (IgM) may not detected (Lepow et al., 2006).
  An ELISA can be used for determination of serum tetanus antitoxin levels. 
It is a simple test, is relatively inexpensive, and can detect antitoxin of specific 
immunoglobulin types. The titer may be higher with ELISA than with 
neutralization assays, especially for recent immunized people suggesting the 
presence of low-avidity antibodies. ELISA has in some hands proven to be as 
sensitive as the neutralization test for the detection of antitoxin, but there are 
problems in reproducibility. Despite the ability of the ELISA to detect IgG 
antitoxin, which presumably contains all of the toxin-neutralization activity, 
differences in binding activity and neutralization have occurred. At this time 
ELISAs should be employed for screening but not for determining the specific titer 
of antibody (Lepow et al., 2006).
     Counterimmunoelectrophoresis can be used for the detection of tetanus 
antitoxin, but because of its relative insensitivity, this method is useful only in 
screening sera containing relatively high levels (>7.0 IU/ml) of antitoxin. A solid-
phase radioimmunoassay has also been described for the detection of tetanus 
antitoxin, but no comparisons with in vivo neutralization testes have been reported.
     It is recommended that in a clinical laboratory, where values for individual 
patients are important, the more reliable mouse neutralization test should be used. 
There is no tissue culture method available for the titration of tetanus toxin or 
antitoxin (Lepow et al., 2006).   
1. 11 Immunology 
1. 11. 1 Natural immunity and Response to disease:
     It is unclear whether humans can develop circulating antibody to tetanus in 
the absence of vaccination or disease. Intestinal colonization could result in such
protection. The exotoxin of C. tetani is so potent and the lethal dose so small that 
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survivors of the disease will rarely develop significant antibodies titers (Lepow et 
al., 2006).       
1. 11. 2 Tetanus toxoid vaccine
     Tetanus vaccines are based on tetanus toxoid. Conventional production 
includes growth of toxigenic strains of C. tetani in a liquid medium that favours 
toxin production, toxin harvest by filtration, detoxification by formaldehyde and
several steps of purification and sterilization. To increase immunogenicity, the 
toxoid is adsorbed to aluminium or calcium salts. Administration of adsorbed 
tetanus toxoid is by intramuscular injection. Tetanus toxoid is stable and can
withstand exposure to temperatures of around 20°C for months and storage at 37°C 
for a few weeks without significant loss of potency. However, the vaccine is 
destroyed in 2 hours at 56°C. Tetanus toxoid-containing vaccines should be stored 
at +4 (2–8) °C; vaccines that have been frozen should not be used (WER, 2006).
1. 11. 2. 1 Toxoid flocculation assay
     International accepted designations of antigen content for toxoid vaccines are 
provided by the WHO in Lf (limes flocculationis or limit of flocculation) and has 
been approved widely for use in vaccines quality control and, as well as for the 
quantification of toxins (Iwaki et al., 2007).
     Methodology for the quantitative flocculation assay involves:
1. 11. 2. 1. 1 Conventional flocculation assay
     For the determination of the Lf value of an unknown sample of tetanus toxin 
or toxoid, increasing volumes of the reference antitoxin are distributed into a series 
of flocculation tubes and the volume is made up to 1 ml of saline. To each tube is 
then added 1 ml of the toxin or toxoid under test and properly mixed by shaking. 
The tube are then put in a water bath held at 50º and placed in such a way that 1/3 
of the tube dips below the water level. The tubes are observed continuously and the 
tube which shows flocculation is noted. The Lf value of the toxin or toxoid is 
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calculated from the concentration of toxin or antitoxin contained in this tube
(WHO, 1977; Iwaki et al., 2007).
1. 11. 2. 1. 2 Blend flocculation assay
     The measurement of very low concentration of toxoid is best carried out by 
the method of blend flocculation. This can be performed in many ways but always 
involves comparison of the Lf value of a known toxoid and that of a mixture of the 
sample with that toxoid (WHO, 1977).
1. 11. 2. 2 Determination of the Minimum Lethal Dose (MLD)
     The M.L.D. of tetanus toxin is that amount of toxin which when injected into 
mice of about 20 g in weight kills the majority in four days. For determination the 
M. L. D. the following method is recommended. One ml of toxin is added to the 
tube No. 1 and well mixed. One ml from tube No. 1 is transferred to tube No. 2 and 
well mixed. One ml from the previous tube is transferred to the next tube until tube 
No. 6 is reached. From tube No. 6, 5 ml of mixture is transferred to tube No. 7 
giving a dilution of 1/2 000 000. One ml of dilutions from tube Nos. 4 to 7 are 
inoculated into mice. If all the mice or at least two-thirds of the mice die on or 
about the fourth day when given the toxin from tube No. 6 the M. L. D. of the toxin 
is taken as 10-6 or 1/1 000 000 (WHO, 1977).   
1. 11. 3 Tetanus toxoid-induced immunity
     Tetanus toxoid induces the formation of specific antitoxins. These antibodies 
play an important role in protecting against tetanus. Immunity to tetanus is antibody
mediated, with tetanus antitoxins, like diphtheria antitoxins, belonging to the 
immunoglobulin G (IgG) class; they are distributed throughout the bloodstream and 
extravascular spaces. Antitoxin in tissues can neutralize toxin produced in an 
infected wound. Antitoxin which passes to the fetus through the placenta following 
active immunization of the mother can prevent neonatal tetanus (Balmer et al., 
2007).
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Although some researchers have suggested that natural immunity against tetanus 
toxin can be induced by gut carriage of C. tetani, the serological and
epidemiological evidence in support of this hypothesis is unconvincing. The only 
reliable immunity against tetanus is that induced by vaccination with tetanus toxoid 
(Martha et al., 2007); Recovery from clinical tetanus does not result in protection 
against further attacks. A small amount of tetanus toxin, although enough to cause 
the disease but is insufficient to stimulate antibody production. Therefore, all 
patients with clinical tetanus should be immunized with tetanus toxoid, either at the 
time of diagnosis or during convalescence (Balmer et al., 2007).     
1. 11. 4 Development of immunity following immunization
1. 11. 4. 1 Immune response to immunization
Tetanus antitoxin response of adults following primary and booster 
immunization with tetanus toxoid shown the degree and duration of immunity 
increases with the number of tetanus toxoid doses given. One dose of tetanus 
toxoid ensures little, if any, protection. Two to four weeks after the second dose the 
mean level of tetanus antitoxin usually exceeds the minimum “protective” level of 
0.01 IU/ml, although the percentage of poorly-protected persons can still be up to 
10%. Immunity also declines with time. After one year the percentage of poorly-
protected persons may increase to 20% and the mean titre may fall to the threshold 
level (Balmer et al., 2007). 
     The infants of women with a suboptimal level of antitoxin may be at risk of 
tetanus. For this reason, a third dose of tetanus toxoid should be given during the 
subsequent pregnancy, or 6 to 12 months after the initial two doses. A third dose of 
tetanus toxoid induces plentiful antitoxin production, with mean levels between 1 
and 10 IU/ml. The level of immunity induced by a course of three injections is high 
and durable. One month following the third dose the percentage of poor responders 
is negligible and the protective level lasts for at least five years. After the third 
dose, each additional dose given with at least a one-year interval increases the 
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tetanus antitoxin level and prolongs the duration of immunity. Immunity will last 
for 10 years after the fourth dose and for at least 20 years after the fifth dose
(Balmer et al., 2007). 
1. 11. 4. 2 Duration of immunity following various immunization schedules
     An understanding of the duration of immunity induced by immunization has 
important implications for the recommendations on the number and timing of doses 
to be given. Most data derive from studies on antibody profiles at different time 
points after vaccination. Data on the duration of clinical protection after 
vaccination in pregnancy, reported from the People’s Republic of Bangladesh, 
suggested that neonatal tetanus mortality rates remained significantly lower in 
women who had received either one or two injections of tetanus toxoid for up to 12 
or 13 years after vaccination. However, these data must be interpreted with caution 
as the vaccination history of the study subjects is uncertain, and the data contradicts 
the widely accepted view that multiple doses are required for long-term protection 
(Balmer et al., 2007).
     The length of long-term protection after five or six doses is uncertain, but seems 
to be at least 20–25 years in populations receiving primary doses in infancy, and 
boosters in childhood and adolescence. Recommended vaccination schedules vary 
by country. WHO recommends that at least five doses of tetanus toxoid vaccine be 
given over 12–15 years, starting in infancy; a sixth dose given in early adulthood is 
encouraged, to ensure long lasting protection (Martha et al., 2007) table 3
     The serological surveys also illustrate the potential for appropriately scheduled 
primary series and boosters to provide high antibody levels for women throughout 
childbearing age. This dose vary by country and immunization schedule, but 
suggests that a complete primary series of immunizations and subsequent boosters 
in childhood and adolescence provides protective antibody levels well into 
adulthood, protecting women (and their newborns) throughout their childbearing 
years (Balmer et al., 2007) hence maternal antibodies are a critical component of 
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the immune system at birth. Beginning at the second half of the second trimester, Ig
is actively transport across the placenta to the fetus by the placental IgG antibodies, 
which also contain idiotypic antibodies (Randolph, 2005).
Table 1: 3 
Tetanus toxoid vaccination schedule for pregnant women and women of 
childbearing age who have not received previous immunisation against tetanus
(Martha et al., 2007)
Optimum dosing 
interval
Minimum acceptable 
dosing
Interval
Estimated 
duration
of protection
Dose 1 At first contact with 
health worker or as 
early as possible in 
pregnancy
At first contact with health 
worker or as early as 
possible in pregnancy
None
Dose 2 6–8 weeks after 
dose one*
At least 4 weeks after dose 
one
1–3 years
Dose 3 6–12 months after 
dose two*
At least 6 months after dose 
two or during subsequent 
pregnancy
At least 5 years
Dose 4 5 years after dose 
three*
At least one year after dose 
three or during subsequent 
pregnancy
At least 10 years
Dose 5 10 years after dose 
four*
At least one year after dose 
four or during subsequent 
pregnancy
All childbearing 
age years; 
possibly longer
*Should be given several weeks before due date if given during pregnancy.
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1. 11. 5. 2 The Placenta as a selective organ
     Tetanus antitoxin transferred from immunized mother to fetus provides 
transient protection of the newborn infant from tetanus. The human placenta 
regulates the transfer of antibodies from mother to fetus in a selective manner
(Balmer et al., 2007); Immunoglobulin G is the only immunoglobulin classes that 
cross the human placenta (Rabson, 2005; Martha et al., 2007). Transport of 
maternal IgG across the placenta and across the neonatal intestinal epithelium is 
mediated by an IgG-specific Fc receptor called the neonatal Fc receptor (FcRn). 
The FcRn is unique among Fc receptors in that it resembles a class I major 
histocompatibility complex (MHC) molecule containing a transmembrane heavy 
chain that is noncovalently associated with β2-microglobulin (Abass, 2006). FcRn 
bind IgG at acidic pHs. Syncytiotrophblast cells pinocytose maternal serum, and 
the pinocytosed vacuoles enter the endosomal pathway, where they are acidified. 
On acidification, the Fc receptors bind the IgG in the serum, prevent its 
degradation, and promote its transport to the plasma membrane, where it is released 
under pH conditions, and The IgG travels across the placental stroma and fetal 
circulation (figure 1: 11).     
     Of the Ig subclassces, IgG1 is transported most efficiently, followed by IgG4, 
IgG3, and IgG2. Of note, neither IgM nor IgA bind neonatal Fc receptors and, thus, 
neither is transferred to the fetus (Randolph, 2005; Martha et al., 2007). Fetal IgG 
antibody levels rise progressively from the fourth month of pregnancy until term
(Balmer et al., 2007). The normal concentrations of the Ig subclassces are shown in 
table 1: 4 (Randolph, 2005).
       The maternal antibodies are vital for protecting the infant during the first 
months after birth. Perhaps the most dramatic evidence of this comes from children 
who have T- and B-cell immune deficiencies and often do not present until a few 
months after birth when maternal protection wanes. The lack of transport of IgM 
and IgA is also of clinical importance because measurement of these classes 
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Figure 1: 11 The epithelial cell surface receptor for immunoglobulin G (IgG) Fc regions. 
The FcRn receptor is present in the placenta where it fulfills the important task of transferring 
maternal IgG to the fetal circulation. This will provide important protection prior to the 
generation of  immunocompetence in the fetus. Furthermore, it is self-evident that any infectious 
agent which might reach the fetus in utero will have had to have passed through the mother first, 
and the fetus will rely upon the mother’s immune system to have produced IgG with appropriate 
binding specificities. This maternal IgG also provides protection for the neonate, because it takes 
some weeks following birth before the transferred IgG is eventually all catabolised (Rabson et 
al., 2005).
Table 1: 4 Typical Concentrations of the Ig Subclasses in Fetues and 
Newborns (Randolph, 2005).
Age IgG1(g/L) IgG2(g/L) IgG3(g/L) IgG4(g/L) IgM(g/L) IgA(g/L)
17 to 22 wk 0.93 0.31 0.05 0.04 0.001
28 to 32 wk 3.7 0.93 0.19 0.21 0.002
Term 10.43 1.56 0.41 0.47 < 0.2 0.004
Adult 10 4 1 0.5 2 2.5
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provides a means to evaluate the infant’s immune responses, as in a suspected 
congenital infection (Randolph, 2005).      
1. 11 .5. 3 Ratio of umbilical cord antibodies to maternal antibodies level
     At birth, the infant usually has a total tetanus antibody concentration equal 
to, or some times higher than, the mother. Munoz & Englund (2001) found the 
concentration of subclass IgG1antibodies can be higher in the cord blood than in 
maternal blood, thus suggesting that there is an active transfer of antibodies in the 
placenta. Early studies found that the tetanus antitoxin levels in cord serum and 
maternal serum were usually equal, although in 20% to 30% of cases the cord 
serum had a lower titre than the maternal serum. This may be attributed to the 
presence of only IgG in neonates, although this observation is dependent upon the 
assay used, as the HA will detect IgG and IgM in mothers and IgG in the newborns. 
It was observed that the cord/maternal ratio of tetanus antibodies are higher in 
European than in African settings. This may be linked to high immunoglobulin 
levels in African mothers exposed to multiple antigenic stimuli (Balmer et al., 
2007).
1. 11. 5. 4 Factors influencing the response to tetanus toxoid and placental   
transfer of antitoxin 
     Two conditions that may influence the immune response to tetanus toxoid 
and placental transfer of antitoxin are malaria and human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS) (Balmer et al., 2007). 
Other factors affect transplacental maternal tetanus antibody transfer. Prematurity, 
severe maternal hypergammaglobulinaemia, and high maternal antitetanus IgG 
concentrations have been associated with reduced cordmaternal ratios of tetanus 
antibody, compared with controls, although these findings have not been consistent 
(Okoko et al., 2001). In many areas where neonatal tetanus is still common, these 
infections are also widespread (Balmer et al., 2007).
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1. 11. 6 “Protective Level” of tetanus antibodies
     For most infections, laboratory markers of immunity which reliably predict 
protection from clinical disease in field studies are used as predictors of vaccine 
efficacy. For clarity, the marker has to consistently predict protection at an 
individual level and actually mediate the protection observed. It has been suggested 
that a surrogate is the measurement of a functionally protective laboratory marker, 
and a correlate is the measurement of a marker, usually by a non-functional assay 
which correlates strongly with the surrogate of protection (Borrow & Miller, 2006). 
Hence, the measurement of toxin-neutralizing antibody would be regarded as a 
surrogate of protection and detection of antitoxin (toxoid) specific IgG would be 
considered a correlate to the surrogate of protection. Surrogates of protection can 
be obtained from studies of natural immunity, Phase III efficacy trials, or passive 
immunization. For tetanus, the existence of natural immunity is questionable, and 
large-scale efficacy studies have rarely been performed with concomitant 
measurement of antibody. These data on protective levels have therefore been 
subject to much debate. It has often been accepted that the minimum level of 
antibody required for protection is 0.01 IU/ml measured by an in vivo 
neutralization assay. They showed that active immunization of guinea pigs induced 
a level of 0.01 IU/ml which prevented death. They extrapolated from these results 
to suggest that a similar level would be protective in humans. It is interesting that 
Sneath et al (1937) noted that 13% of guinea pigs developed clinical tetanus despite 
antibody levels as high as 0.1 to 0.5 IU/ml. Actual data from human studies are 
limited. Wolters & Dehmel (1942) immunized themselves, determined their 
antitoxin levels to be 0.007 to 0.01 U/ml and then challenged themselves with “2–3 
fatal” doses of Cl. Tetani spores without experiencing any clinical symptoms. As it 
is unclear as to the level of toxin required to cause infection, interpretation of these 
data should be cautious. Supporting evidence for 0.01 IU/ml as the protective
threshold is limited. Looney et al (1956) summarized the attempts made to 
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determine a protective level of antitoxin by reviewing various studies on active 
immunization experiments in guinea pigs and horses, and passive immunization 
data, and concluded that “no final answer is at hand”. The experience of the British 
army during the First World War, where levels of approximately 0.03–0.06 U/ml
were achieved by administration of antitoxin and few cases of tetanus occurred in 
soldiers, has been interpreted as suggesting that those levels were protective. 
Tasman & Huygen (1962) suggested again that 0.01 U/ml was appropriate for 
protection following a review of the literature and applied this criterion to their 
study of active immunization of patients treated with anti-tetanus serum. Further 
support for a protective level is given by the study of MacLennan et al (1965) who 
reported that a maternal antitoxin level at delivery of 0.01 IU/ml, determined by a 
neutralization assay, is protective. The difficulty in assigning a definitive level of 
antibody for protection is illustrated by the number of cases of tetanus that have 
occurred in individuals with antibody levels greater than 0.01 IU/ml by 
neutralization assay, or 0.15 IU/ml by ELISA (Balmer et al., 2007).  
     Other approaches to defining a correlate of protection include taking a 
population-based approach, in which a comparison is made between antibody 
levels in a protected group (immunized), versus a susceptible (non- or partially-
immunized) group. An antibody level that is exceeded by the majority of the 
protected individuals and not by the majority of the susceptible population should 
be validated against the relative risk of disease at the defined titre. This has been 
illustrated for pertussis and respiratory syncytial virus (RSV) (Siber, 1997), 
meningococci (Borrow & Miller, 2006) and pneumococci. To date, such studies 
have not been performed for tetanus, and the relatively rare occurrence of tetanus, 
combined with the lack of a fully standardized and readily used assay that 
correlates with toxin neutralization, would make these studies difficult (Balmer et 
al., 2007).  
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     In summary, the minimum amount of circulating antitoxin that in most cases 
ensures immunity to tetanus is assay-specific. With in vivo neutralization tests or 
modified ELISA assays, concentrations exceeding 0.01 IU/ml are usually 
considered protective, whereas antitoxin concentrations of at least 0.1–0.2 IU/ml
are defined as positive when standard ELISA techniques are used for this 
assessment. Cases of tetanus have been documented, however, in persons with 
antitoxin concentrations above these thresholds. Hence, a “protective antibody 
concentration” may not be considered a guarantee of immunity under all 
circumstances. The aim should be to sustain high antibody concentrations 
throughout life (Balmer et al., 2007).  
1. 12 Treatment of tetanus
Management of generalized tetanus aims to (Galazka et al., 2004):
 Neutralize any toxin still present in the blood before it comes into contact 
with the nervous system. This is accomplished by the promptadministration 
of tetanus antitoxin.
 Prevent further toxin production by eliminating the organism at the infected 
site. This can be done by the thorough debridement of wounds, excising all 
devitalised tissue and removing all foreign bodies. Antibacterial therapy with 
antibiotics is routinely used to reduce the number of vegetative forms of the 
organism.
 Provide constant and meticulous nursing and medical care. Along with      
assisted ventilation, many tetanus patients are managed with heavy           
sedation, muscle relaxants and curare-like drugs, and drugs that reduce the 
hyperactivity of the autonomic nervous system.
 Closely monitor fluid, electrolyte, and caloric balance, especially in
neonates and other patients with repeated seizures or inability to take food or 
liquids because of severe trismus, dysphagia or hydrophobia.
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 Prevent recurrence through vaccination. Since the disease does not stimulate 
the development of immunity against further attacks, every patient should be 
given an injection of tetanus toxoid followed by a second dose after at least 
4 weeks and a third dose 6 to 12 months after the second dose.
1. 13 Prevention
     Maternal and neonatal tetanus prevention relies on avoidance of unsafe delivery, 
abortion, and umbilical cord care practices, and promotion of maternal tetanus 
immunisation. The powerful effect that puerperal and umbilical stump hygiene 
have on prevention of neonatal tetanus is evident from the history of developed 
countries before the availability of tetanus toxoid. In the first half of the 20th 
century, neonatal tetanus in Denmark and the USA steadily decreased to 0·05 and 
0·02 cases per 1000 livebirths, respectively, as health facility deliveries and 
hygienic obstetric and cord-care practices became widespread. Even in rural 
regions of the developing world where home deliveries are common, concerted 
efforts to educate health workers and pregnant women about safe deliveries and 
care of neonates can result in substantial reductions in neonatal tetanus (Martha et 
al., 2007).
     A notable example is a controlled trial in Maasai villages in Kenya and 
Tanzania where a reduction in annual neonatal tetanus incidence from 80 to 0·75 
per 1000 livebirths was achieved with the introduction of a programme promoting 
clean delivery practices, and the replacement of cow dung for postnatal umbilical-
cord care by clean water or milk, both culturally acceptable and safer alternatives. 
The incidence of neonatal tetanus remained below 1·0 per 1000 per year in the 
intervention villages throughout a decade of observation, while remaining 
unchanged in control villages (Meegan et al., 2001). An analysis of interventions 
aimed at the improvement of neonatal survival estimated that 75–85% of deaths 
from neonatal tetanus could be prevented through the effective implementation of a 
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family-based package of interventions that included clean home deliveries and 
hygienic cord care (Darmstadt et al., 2005).
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CHAPTER TWO
MATERIALS AND METHODS
2.1 Study design
       This is a descriptive hospital-based and Cross-sectional study.
2. 2 Study area
       Omdurman Maternity Hospital.
2.3. Study population
       One hundred pregnant women that regularly visited Maternity Hospital and 
their newborns were included. Their age range from 14 – 40 years. The study 
population was divided into groups according to age (3 age groups), area of 
resident (6 areas), level of education (4 education level) and ethnic group (6 tribal 
groups).   
2. 4. Study procedure
2. 4. 1 Interview
       Questionnaire form was designed in 12 questions included general information 
about the mothers' age, parity including their current pregnancy, number of TT 
doses received during pregnancies and malaria status were recorded. Informed 
consent was obtained from all mothers participated in this study and during the 
interview all informations were collected. 
2.4. 2 Sampling
2. 4. 2. 1 Sample size
       A sufficient sample size was calculated by the Epi Info program version 6.  
Two hundred (200 mothers and their 200 newborns) samples were found justified 
by taking probability of type 1 error of 5% (confidence level or = 95%), and the 
power of the power equal to 80%. 
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2. 4. 2. 2 Sample collection and storage
       A blood sample was taken from healthy pregnant women upon admission to 
the Omdurman maternity hospital above. Maternal venous blood (4 ml) was 
collected from a peripheral vein immediately before or after delivery.
       Following delivery, a cord blood sample also was obtained from all newborn. 
Four ml volume cord blood was collected from large veins on the foetal side of the 
placenta immediately after delivery. 
       All blood samples were labeled. Sera was separated from these samples and 
stored at ̶ 20 °C until assayed for specific anti-tetanus IgG antibodies. The level of 
specific antibodies (IgG) was determined by in house ELISA. 
2. 5 Materials
2. 5. 1 In house ELISA for the detection of anti-tetanus antibodies in sera of 
mother and their newborn.
2. 5. 2 Preparation of solutions and buffers
2. 5. 2. 1 phosphate buffered saline (PBS), pH 7.2, 0.15M
Prepared by mixing 8.00 g Sodium chloride, 0.20 g Potassium chloride, 
1.15 g Di-sodium hydrogen phosphate, 0.20 Potassium di-hydrogen phosphate and 
dissolve in 1000 ml D.W.
2. 5. 2. 2 Tween 80
A solution 0.01% Tween 80 was prepared in distilled water.
2. 5. 2. 3 Bovine serum albumin (BSA) was obtained as freeze-dried (Sigma)  
2. 5. 2. 4 Preparation of antigen
     Tetanus toxoid vaccine was used as coating antigen. The vaccine was 
obtained from Expanded Immunization Programme the Federal Ministry of Health, 
Khartoum, Sudan.
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2. 5. 2. 5 Coating buffer 
       Carbonate- bicarbonate buffer, pH 9.6 (coating buffer), was prepared by 
adding 1.59 g of Na2CO3 and 2.93 g of NaHCO3 to 1 liter of distilled water.
2. 5. 2. 6 Blocking buffer
      It was prepared as 2% BSA in PBS.
2. 5. 2. 7 Dilluent buffer
      The dilluent that used for sample dilution was PBS containing 0.5% BSA 
and 0.05%Tween 80 (PBS-Tween80).
2. 5. 2. 8 Stop solution 
    1N HCL was used for stopping the enzyme reaction. 85.85ml of 36% HCL 
was completed to one liter by adding distilled water to give 1N HCL.
2. 5. 3 Positive control (Reference antiserum) 
      Tetanus Immunoglobulin B. P (Human TETGLOB® 250 I.U. Bharat serum 
and vaccines limited India) was used as positive control and to draw Standard 
curve. Dilutions of TIG (250 IU/ml) were prepared in (PBS-T) so that the final 
concentrations were 6.4, 3.2, 1.6, 0.8, 0.4, 0.2, 0.1, and 0.05 U/ml.
1ml (TIG) = 250 U/ml
6.4 U/ml  100 µl = 0.64 U/well
Stock 1ml (TIG) + 3ml (PBS-T) = 62.5 µ/ML
1 x 62.5 = X 6.4
X = 9.77
0.1 ml + 0.877  6.4 U/ml
Then we take 100 µl and inserted into first well  0.64 then we prepared a twofold 
dilution.
2. 5. 4 Enzyme Conjugate (Tetanus Toxoid IgG Conjugate)
        Horseradish peroxidase-conjugated IgG fraction of polyclonal goat antiserum 
to human IgG, heavy and light chains, Product code: GAHu/IgG (H+L)/PO, was 
obtained from Nordic Immunological Laboratories, Netherlands. The conjugate is 
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reconstituted by adding 1 ml sterile distilled water, divided into aliquots in 10 tubes 
0.1 ml in each tube, frozen and stored at or below -200. 
For performing the ELISA tests 1/5000 dilution of the conjugate was prepared.  
2. 5. 5 Preparation of the Substrate-chromogen
        OPD (o-phenylenediamine dihydrochloride) Peroxidase Substrate _ (Tablet 
Sets _ Sigma, Cat # P-8412) was used. The 30mg substrate tablet was dissolved in 
75ml 0.05M Phosphate-citrate buffer, PH 5.0 to give a concentration of 40mg/ml as 
recommended by the manufacture.  
0.4 µl of fresh 30% hydrogen peroxide per100ml of substrate buffer solution was 
added immediately prior to use. 
2. 5. 6 ELISA Plate layout (Table 2: 1)
2-fold
Dilution
1 2 3 4 5 6 7 8 9 10 11 12
A SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
B SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
C SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
D SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
E SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
F SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
G SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
H SM1 SC1 SM2 SC2 SM3 SC3 SM4 SC4 SM5 SC5 PC NC
Key:
SM = Mother sample PC = Positive Control
SC = Cord sample NC = Negative Control 
Note: Mother and cord sera were run in the same ELISA plate to avoid differences 
between plates.
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2. 6 Assay Procedure
       The WHO acknowledges the ELISA test as the criterion standard. We used 
the indirect ELISA based essentially on method described for the determination of 
diphtheria and tetanus antibodies (WHO, 1997) with some modification by Aybay 
(2003).   
2. 6. 1 Coating of immunoassay plates
An in-house ELISA for anti-tetanus toxoid IgG antibody was conducted 
using 96-well Flat-Bottom Plates (Nunc-immuno plate, Germany). It was a High 
protein-binding capacity since low protein binding capacity plates gives low signal 
yield. Tetanus toxoid was diluted to a final concentration of 2.5 Lf/ml in carbonate 
buffer, and 100µl was dispensed into wells. The plate was tightly covered and 
incubated for 1 h at 37°C and at 4° C overnight.  
2. 6. 2 Plate washing
Plates are washed at the end of each incubation period before the addition of 
the next reagent or analyte. The quality of the final result is dependent on the 
efficacy of the washing procedure. Three methods are in common use. In this 
protocol the hand washing method is used.
The plate was taken from the incubator. All the wells was filled with 200 µl 
of washing buffer (PBS) using a multichannel pipette. The plate shacked gently for 
2 minutes by tapping at the sides. The contents of the plates was shacked out and 
banged dry against absorbent paper. This procedure was repeated three times.
2. 6. 3 Blocking
All the wells were blocked with 125 µl of blocking buffer and incubated for 
1 hour at 37০ C and then washed.
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2. 6. 4 Serum dilutions
       Two-fold serum dilutions were prepared starting at column 1 through to 
column 8. All sera were diluted 1/100 in advance by adding 10 µl of serum to 990 
µl of diluent (for this the Micronic tube system offers some advantages). 
Standards (6.4 IU/ml, 3.2 IU/ml, 1.6 IU/ml, 0.8 IU/ml, 0.4 IU/ml, 0.2 IU/ml, 0.1 
IU/ml, and 0.05 IU/ml) anti-tetanus antibodies were included in parrel wit test 
sample as positive controls and diluent buffer alone was also tested as a negative 
control. 
Plates were incubated for 1.5 hour at 37০ C and washed. 
2. 6. 5 Conjugate
To detect antibodies bound to the coated tetanus toxoid, a conjugate was 
added to each well. 100 µl of 1/4 000 dilution of conjugate was added to all wells, 
and the plate covered and incubated for 1 hour at 37০ C and washed.  
2. 6.  6 Substrate addition
    Substrate OPD activated immediately before use with hydrogen peroxide 
was added. Then 100 µl of the substrate was carefully added to all wells due to its 
sensitivity to direct sun light. The plate incubated at room temperature for 10- 20 
minutes, the Substrate gives colour gradually due enzyme reaction.  
2. 6. 7 Stopping buffer addition
      The enzymatic reaction was stopped by added 100 µl of the 1N HCL to each 
well. 
2. 6. 8 Reading of ELISA plates
      The absorbance value was read at 492 nm in ELISA plate reader (Rayto RT-
6100, China). 
2. 6. 9 Evaluation of results  
    The absorbance obtained for the test samples were transformed into antibody 
units expressed as IU/ml (international units per milliliter), using standard curves.
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       Standard curve was generated for each plate and optical densities of test sera 
dilutions falling within the linear part of the curve were interpolated and expressed 
in IU/ml as depicted in figure (1) below.
Figure 2: 5 Calibration of Standard Curve
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Plot the control coordinates and determine the best-fit line. Using the 
absorbance data and standard curve as a guide, it was possible to determine the 
approximate IU for each sample. Once the IU value has been determined from the 
graph, this value was multiplied by the dilution factor of the sample. 
2. 6. 10 Protective Level of the anti-tetanus antibodies
        The WHO acknowledges the ELISA test as the criterion standard, with a 
threshold of 0.1 IU/ml, to diagnosis tetanus immunization status (Colombet et al., 
2005).
       Tetanus antitoxin levels were classified according to the generally adopted 
protective levels, < 0.1 IU/ml no protection, ≥ 0.1 – 0.9 IU/ml minimal protection, 
≥ 1.0 full protection. 
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2. 6. 11 Statistical analyses of the result
       The data was analyzed using statistical package of social sciences SPSS 
version 11.5. 
         Results are expressed as mean and standard deviation. The significance of 
the mean difference between two paired groups was determined using Paired 
Sample t test The significance of difference between two mean values among cases 
and control group were determined by the Student independent t -test, or ANOVA 
if we compare more than two means with p<0.05 considered significant.
Significance testing of difference between proportions was conducted using 
the Chi-square test, adjusted by Pearson's or Fisher's exact test, depending on the 
number of observations, with a value corresponding to p <0.05 for significance 
unless otherwise stated. 
For quantitative, normally distributed variables, we choose the Pearson 
correlation coefficient. For not normally distributed data or ordered categories, we 
choose Spearman correlation, which measure the association between rank orders. 
Correlation coefficients (r) range in value from 1 (a perfect negative relationship) 
and +1 (a perfect positive relationship) A value of 0 indicates no linear relationship. 
This test did not provide a cause -effect relationship.
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CHAPTER THREE
RESULT
3. 1 Questionnaire findings
       A total of 200 mothers-newborns pairs in Omdurman Maternity Hospital were 
included in this study. A detailed description of mother's characteristics age, 
residence, ethnic groups, education, parity, tetanus toxoid vaccination, and malaria 
infection were provided in figure 3:1 to 3:9 respectively. 
3. 2 Tetanus toxoid antibody levels in mother and newborn babies 
Figure 3:7 showed the distribution of the study samples according to their 
protection level. In 34.5% of pregnant women and 32.5% of their newborn were 
found to have full protective levels of tetanus antibodies (≥1.0 IU/ml). In 63% of 
pregnant women and 65% of their newborn, antibody levels detected, ranged 
between ≥ 0.1 and 0.9 IU/ml and were accepted as the minimal protection level. In 
2.5% of pregnant women and also 2.5% of their newborn, antibody levels were     
< 0.1 IU/ml, which was defined as non-protective and both were at risk of tetanus.  
The mean difference between mother and newborn tetanus antibody levels 
illustrated in figure (3:12). Mean mother titer was (.923, SD=1.02), while mean 
newborn titer was (1.438, SD=1.82). The mean difference was 0.515 (SD= 1.06), 
and it was statistically significant (p value = 0.00). 
3. 2 Maternal age groups and TT antibody level in mother and newborn 
In figure (3:1) maternal age ranged from 14 to 40 years (mean age 25.9 ± 5.9 
years). 50% mothers were at age group 23 – 31, 31% were at age group 14 – 22, 
and 19% were at age group 32 – 40.
Table (3:1) illustrated the mean mother TT antibody level in relation to 
various factors. In the 14-22, 23-31 and 32-40 age groups, the effect on mean TT 
antibody levels showed statistically significance difference and the mean TT 
antibody levels were 0.63 IU, 1.13 IU and 0.84 IU respectively (P= 0.001). When 
the age groups were compared according to their immune status, differences were 
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significant and showed trend. Immune status was found to be full in 23-31 age 
groups and decreased to minimum protective level in the 32-40 and 14-22 years of 
age groups respectively. 
Maternal age groups (14-22, 23-31, and 32-40) had highly significant effect 
on the maternal-to-cord antibody mean ratio and we found higher cord antibody 
levels than maternal level (1.75 IU, 1.53 IU, 1.14 IU) respectively (P= 0.00), and 
all age groups had full protective antibody level (table 3:1 & figure 3:9). The 
protective TT antibody levels in the newborn are shown in table (3:3).
3. 3 Effect of number of TT vaccination on mother’s TT antibody level and 
maternal-to-cord TT antibody ratio 
According to the statements of the subjects, the rate of those vaccinated 
against tetanus was 94.7% and 5.3% were non vaccinated. Among those vaccinated 
there were 42% (n = 85) received 1-2 doses, 40% (n = 80) received 3-5 doses, 15% 
(n = 30) received >5 doses and 25% (n = 5) received none as shown in figure (3:6) 
& table (3:1).
Women who had 3-5 doses had significantly higher mean (1.79 IU/ml) TT 
antibody levels than those who had 1-2 doses (0.33 IU/ml) and those who had >5 
doses had relatively lower TT antibody levels than those who had been vaccinated 
with 3-5 TT doses (table 3:2). Whereas the number of TT doses received by 
mother’s had no significant effect on maternal-to-cord TT antibody ratio (table 
3:7).
Table (3:4) illustrated the relationship between newborns protection of TT 
antibody levels and number of doses received by the mother’s. Five  mother’s who 
had not received any dose of TT vaccine doses their newborns were 100% non-
protected, whereas 83 (97.6%) mother’s who had received 1-2 doses TT vaccine 
their newborns found to have minimal protection and only two (2.4%) were fully 
protected. On the other hand 18 (22.5%) mother’s who had received 3-5 doses of 
TT vaccine found to have minimal protection and 62 (77.5%) were fully protected. 
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Moreover 29 (96.7%) mother’s who had received more than 5 doses of TT 
vaccine their newborns have minimal protection and only one mother (3.3%) her 
newborns was fully protected. There was statistically significant strong positive 
correlation between maternal and neonatal antibody titre (P= 0.0) as depicted in 
figure (3:12).  
3. 4 Effect of multiparous vs. primiparous on the mother TT antibody levels 
and the maternal-to-cord TT antibody ratio
The mean number of pregnancies was 2.9 and standard deviation (SD) 2 
[range from 1 to 11].   
Figure (3:5) showed that 64% (n = 129) were multiparous and 36% (n = 71) 
were primiparous. Mother’s parity had significantly higher mean TT antibody 
levels in multiparous women (1.28 IU) than primiparous women (0.28 IU) as 
shown in table (3:2) and figure (3:5).
Multiparous women had lower N/M TT antibody level ratio 1.45 than did 
primiparous mothers 1.67 as shown in table (3:7) and figure (3:10).
3. 5 Effect of malaria infection on mother’s TT antibody levels and maternal-
to-cord TT antibody ratio 
From figure (3:8) the prevalence of malaria infection among mothers was 
11% and those negative for malaria were 89%. Malaria infection in mother’s had 
no significant effect on mean TT antibody levels but from table (3:4) and figure 
(3:8) mothers with placental malaria infection transmitted signiﬁcantly lower levels 
of TT antibody levels to their newborns (0.49 IU/ml) than did mother without 
malaria infection (1.56 IU/ml). Newborn-maternal antibody ratio in malaria 
infected women was (0.59) whereas in malaria non-infected women newborn-
maternal TT antibody ratio was (1.64) which is statistically significant (P= 0.00) as 
shown in table (3:7) and figure (3:8) and (3:11).
3. 6 Effect of place of residence, ethnic groups and education status on 
mother’s TT antibody levels and maternal-to-cord TT antibody ratio 
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From figure (3:2) all mothers were resident in Omdurman: 55% in west 
Omdurman, 16% in North Omdurman, 15.5% in South Omdurman, 9% in East 
Omdurman, and 4.5% in Centre Omdurman.
Figure (3:3) showed the distribution of mother according to their ethnic 
groups: 33% were from Central tribes, 28.5% were from Northern tribes, 22.5% 
were from Western tribes, 13% were from Southern tribes, 2.5% were foreigners, 
and 0.5% were from Eastern tribes. Figure (3:3) and table (3:6) showed that ethnic 
groups had no effect on antibody level or maternal-to-cord TT antibody ratio.
For categorizing educational status as shown in figure (3:4) we observed that 
12% were illiterate, 36% had primary school, 27.5% had secondary school, and 
24.5% had university education. Place of residence, ethnic groups and education 
status had no significant effect on mean TT antibody level (table 3:1) and figure 
(3:2), figure (3:3), and figure (3:4).
Educated mother’s transmitted signiﬁcantly higher levels of TT antibody 
levels to their newborns than illiterate mother’s. Also in table (3:6) we observed 
that, mother’s education had significant effect on the maternal-to-cord TT antibody 
ratio. Probably due to number of doses of TT vaccine received in each category. 
Maternal residence and ethnic groups had no effect on the maternal-to-cord 
TT antibody ratio (table 3:6).
- 47 -
Figure 3: 1 Distribution of the study sample according to mothers' age and effect of age on 
protective TT antibody level
Note:
Mean Age (SD): 25.9 (5.8)
Range: 14 - 40 years
Protective anti-tetanus antibodies in mothers Protective anti-tetanus antibodies in newborns
Group 1 age (14-22) yrs = 0.63 IU/ml
Group 2 age (23-31) yrs = 1.13 IU/ml
Group 3 age (32-40) yrs = 0.84 IU/ml
1.19 IU/ml
1.72 IU/ml
1.08 IU/ml
Figure 3: 2 Distribution of the study sample according to residence and effect of place of 
residence on the protective tetanus antibody levels
Protective anti-tetanus antibodies in mothers Protective anti-tetanus antibodies in newborns
West-Omdurman 1.04 IU/ml
North-Omdurman 0.91 IU/ml 
South-Omdurman 0.70 IU/ml
East-Omdurman 0.58 IU/ml
Centre-Omdurman 1.06 IU/ml
1.66 IU/ml
1.32 IU/ml
0.89 IU/ml
0.96 IU/ml
1.97 IU/ml
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Figure 3: 3 Distribution of the study sample according to ethnic groups
and effect of ethnic groups on the protective tetanus antibody levels
Protective anti-tetanus antibodies in mothers Protective anti-tetanus antibodies in newborns
Centreal ethnic groups 0.81 IU/ml
Northern  ethnic groups 0.99 IU/ml 
Western ethnic groups 1.01 IU/ml
Southern ethnic groups 0.98 IU/ml
Foreigner ethnic groups 0.88 IU/ml
1.15 IU/ml
1.52 IU/ml
1.79 IU/ml
1.51 IU/ml
1.08 IU/ml
Figure 3: 4 Distribution of the study sample according to mothers' education level and 
effect of level of education on the protective tetanus antibody levels 
Protective anti-tetanus antibodies in mothers Protective anti-tetanus antibodies in newborns
Illiterate 0.73 IU/ml
Primary 0.88 IU/ml 
Secondary 0.87 IU/ml
University+ 1.14 IU/ml
0.85 IU/ml
1.33 IU/ml
1.52 IU/ml
1.80 IU/ml
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Figure 3: 5 Distribution of the study sampel according to mothers' parity and effect of the 
parity on the protective tetanus antibody level
Mean number of pregnancies (SD): 2.9 (2) [range from 1 to 11].
Mean TT antibody levels: multiparous (1.28 IU), primiparous (0.28 IU)
Figure 1: 6 Distribution of the study sample according to dose of TT received and the effect 
of no. of vaccination on the protective tetanus antibody levels
0.33 IU
1.79 IU
0.43 IU
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Figure 1: 7 TT protection antibody level in mother and their newborns
Non protection        = <0.1 IU/ml
Minimal protection = between ≥0.1 & 0.9 IU/ml
Full protection        = ≥1.0 IU/ml
Figure 3: 8 Distribution of the study sample according to malaria infection and the effect of 
malaria infection on the protective TT antibody level
Protective anti-
tetanus antibodies 
in mothers
Protective anti-
tetanus antibodies in 
newborns
ratio
Non-infected 0.93 IU/ml 1.56 IU/ml 1.64 IU/ml
Infected 0.90 IU/ml 0.49 IU/ml 0.59 IU/ml
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Figure 3: 9 Comparison of Neonatal / Maternal antibody ratio with different age groups 
(Statistically significant, p =0.00)
Figure 3: 10 Comparison of Neonatal / Maternal antibody ratio in relation to parity 
(Statistically significant, p = 0.01)
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Figure 3: 11 Comparison of Neonatal / Maternal Antibody Ratio related to the Malaria 
infection (Statistically Significant, p = 0.00)
Maternal TT antibody level (IU/ml)
Figure 3:12 Linear correlation between Maternal and Neonatal TT antibody titer (strong 
positive correlation, PC= 0.87. Statistically significant, P =0.00)
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Table 3: 1 Mean mother protective TT§ antibody level in relation to 
demographic characteristics
Mean TT
(IU/ml)
95% CI P value
Lower 
Bound
Upper 
Bound
Mothers' Age 14 - 22 yrs 0.63 0.43 0.83 0.001*
23 – 31 yrs 1.13 0.91 1.35
32 – 40 yrs 0.84 0.53 1.14
Residence West-Omdurman 1.04 0.83 1.24 0.292
North-Omdurman 0.91 0.57 1.25
South-Omdurman 0.70 0.43 0.98
East-Omdurman 0.58 0.11 1.06
Center-Omdurman 1.06 0.26 1.86
Ethnic groups Central Tribes 0.81 0.58 1.04 0.833
Northern Tribes 0.99 0.69 1.28
Western Tribes 1.01 0.69 1.32
Southern Tribes 0.98 0.56 1.40
Foreigners 0.88 0.01 1.75
Mothers'
Education
Illiterate 0.73 0.33 1.14 0.325
Primary 0.88 0.66 1.09
Secondary 0.87 0.61 1.13
University+ 1.14 0.79 1.50
(Total No. 200)
* Statistically significant, p value <0.05
TT§ : Tetanus Toxoid
 5 mothers were unvaccinated and have no detectable TT antibody in their sera. 
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Table 3: 2 Mean mother protective TT§ antibody level in relation to mothers' 
parity, TT dose and malaria infection
Mean TT 
(IU/ml)
95% CI P value
Lower 
Bound
Upper 
Bound
Mothers' Parity Multiparous 1.28 1.08 1.47 0.00*
Primiparous 0.28 0.25 0.31
TT§ Dose 1-2 Doses 0.33 0.23 0.43 0.00*
3-5 Doses 1.79 1.57 2.01
> 5 0.43 0.21 0.66
Malaria Infection Negative 0.93 0.78 1.08 0.910
Positive 0.90 0.44 1.36
(Total No. 200)
*Statistically significant, p value < 0.05
**Protection Level: ≥ 0.1 IU\ml
TT§: Tetanus Toxoid
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Table 3: 3 Mean newborn protection TT** antibody level in relation to 
demographic characteristics 
Mean TT
(IU/ml)
95% CI P value
Lower 
Bound
Upper 
Bound
Mothers' Age 14 - 22 yrs 1.19 0.79 1.60 0.08
23 – 31 yrs 1.72 1.32 2.12
32 – 40 yrs 1.08 0.57 1.6
Residence West-Omdurman 1.66 1.28 2.04 0.15
North-Omdurman 1.32 0.73 1.92
South-Omdurman 0.89 0.52 1.26
East-Omdurman 0.96 0.19 1.72
Center-Omdurman 1.97 0.29 3.64
Ethnic groups Central Tribes 1.15 0.75 1.54 0.52
Northern Tribes 1.52 1.03 2.01
Western Tribes 1.79 1.15 2.44
Southern Tribes 1.51 0.76 2.25
Foreigners 1.08 -0.4 2.59
Mothers' 
Education
Illiterate 0.85 0.23 1.48 0.18
Primary 1.33 0.97 1.68
Secondary 1.52 1.01 2.03
University+ 1.80 1.16 2.44
(Total No. 200)
*Statistically significant, p value <0.05
**TT: Tetanus Toxoid
 5 NB whose mothers were unvaccinated have 0.01 IU/ml (100% unprotected).
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Table 3: 4 Mean Newborn protection TT antibody level in relation to mothers' 
parity, TT dose, malaria infection and maternal protection
Mean TT 
(IU/ml)
95% CI P value
Lower 
Bound
Upper 
Bound
Mothers' Parity Multiparous 1.98 1.61 2.34 0.00*
Primiparous 0.46 0.39 0.53
TT** Dose 1-2 Doses 0.5 0.35 0.65 0.00*
3-5 Doses 2.88 2.42 3.33
> 5 0.5 0.29 0.71
Malaria 
Infection
Negative 1.56 1.28 1.84 0.01*
Positive 0.49 0.26 0.72
Maternal 
Protection**
Basic Protected 0.41 0.37 0.46 0.00*
Full Protected 3.41 2.96 3.87
(Total No. 200)
*Statistically significant, p value <0.05
**Protection Level: ≥0.1 IU\ml
 5 unvaccinated mothers have no detectable TT antibody in their sera nor in sera of their 
newborn. 
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Table 3: 5 Relationship between Newborn protection and the number of TT§
vaccine doses received by the mother 
(Total No. 200)
(Statistically significant, P value=0.00)
TT§: Tetanus Toxoid
Protection Level
No. of Vaccine Doses
Non 1-2 3-5 > 5 total
Non Protected 5(100.0%) 0.0% 0.0% 0.0% 5
Minimally Protected 0.0% 83(97.6%) 18(22.5%) 29(96.7%) 130
Fully Protected 0.0% 2(2.4%) 62(77.5%) 1(3.3%) 65
Total 5 85 80 30 200
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Table 3: 6 Mean N\M§ ratio in relation to demographic characteristics
Mean
Ratio
95% CI P value
Lower 
Bound
Lower 
Bound
Mothers' 
Age
14 - 22 yrs 1.75 1.61 1.90 0.00**
23 – 31 yrs 1.53 1.41 1.65
32 – 40 yrs 1.14 0.99 1.30
Residence West-Omdurman 1.55 1.44 1.66 0.23
North-Omdurman 1.44 1.22 1.65
South-Omdurman 1.36 1.12 1.60
East-Omdurman 1.75 1.37 2.13
Center-Omdurman 1.61 1.15 2.07
ethnic 
groups
Central Tribes 1.44 1.29 1.60 0.60
Northern Tribes 1.60 1.43 1.77
Western Tribes 1.58 1.41 1.76
Southern Tribes 1.50 1.25 1.75
Foreigners 1.30 0.47 2.13
Mothers' 
Education
Illiterate 1.17 0.92 1.42 0.01*
Primary 1.61 1.45 1.76
Secondary 1.63 1.48 1.78
University+ 1.46 1.29 1.63
(Total No. 200)
*Statistically significant, p value <0.05
N\M§ ration: newborn\ mother TT antibody ration
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Table 3: 7 Mean N\M§ ratio in relation to mothers' parity, TT dose, malaria 
infection and maternal protection
Mean
Ratio
95% CI P value
Lower 
Bound
Lower 
Bound
Mothers' Parity Multiparous 1.45 1.34 1.55 0.01*
Primiparous 1.67 1.51 1.82
TT** Dose 1-2 Doses 1.57 1.43 1.72 0.13
3-5 Doses 1.58 1.45 1.71
> 5 1.32 1.10 1.54
Malaria Infection
         
Negative 1.64 1.56 1.72 0.00*
Positive 0.59 0.50 0.68
Mothers' Protection Minimally Protected 1.51 1.40 1.62 0.11
Fully Protected 1.59 1.45 1.73
(Total No. 200)
*Statistically significant, p value <0.05
N\M§ ratio: newborn\ mother TT antibody ration
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CHAPTER FOUR
DISCUSSION
Tetanus still remains a significant health problem in developing countries. It 
is a serious disease with high mortality rate but it is easily prevented by 
vaccination. Neonatal tetanus may be responsible for 20 – 30% of cases and 70% of 
deaths (Dundar et al, 2005). The most effective way of preventing neonatal tetanus 
is by antinatal vaccination of pregnant mothers as advised by WHO (2000). It is 
generally accepted that the antibody against tetanus toxin cannot be conferred 
naturally and that antitoxin detected in human sera is exclusively induced by 
vaccination (Coplu et al, 2004).
Immunization against tetanus in the Sudan started in 1976 and implemented 
as routine immunization in 1994 in parallel with polio eradication campaign (El 
Sayed, 2006).
The objective of our study is to evaluate the efficiency of TT immunization 
programme of pregnant mothers using an elaborated in-house ELISA to measure 
the protective TT antibody in sera of mothers and cord blood of their neonates. We 
used ELISA, since the test is suited to analyzing large number and is known to 
provide reliable results as reported previously by Manghi et al (1994). In this study 
analyzed the influence of age, parity, number of doses of immunization, area of 
residence, ethnic group and level of education on mothers TT serum antibody 
levels and on placental Transfer of TT antibody in randomly selected mothers and 
their newborns at Omdurman Maternity Hospital. Although vaccinating pregnant 
women is one of the major ways of protecting against neonatal tetanus and 
vaccinations coverage alone are often considered inaccurate indicators of a 
population’s protection, since they did not reflect the actual biological level of 
protective immunity. Measuring serum antibody level that yields a more accurate 
estimate of the population protection is a good method to monitor the effectiveness 
of any vaccination strategy for pregnant women. In our study all immunized 
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pregnant women have developed a protective antibody level in their sera (table 1). 
These findings are in agreement with previous studies that have documented that 
tetanus immunization during pregnancy produces effective and protective 
seroconversion rate of 98% in pregnant women who were given two doses of TT 
vaccine at one-month-interval (Anh et al., 1999). It is clear that most of women 
studied had received the full primary vaccine series or appropriate TT booster. the
results also indicated that one dose of TT vaccine during pregnancy can be 
effective, since women who received one and women who received two doses of 
TT had a comparable protective antibody level and neonatal mother TT antibody 
ratio as shown in table (3:1), (3:2), (3:5), (3:6) and (3:7) as well as in figure (3:6),
(3:9), (3:10) and (3:12) 
The study demonstrated that, TT antibody level in both studied pregnant 
women and their newborns were above the threshold level defining protection and 
seropositivity as show in table (3:1), (3:2) and table (3:3), (3:4). Those who did not 
receive TT vaccine showed no protection antibody level < 0.01 IU/ ml. levels of TT 
antibodies were significantly high in mothers (P= 0.001) who had received single 
or multiple doses of TT vaccine. Similarly placental transfer of TT antibody was 
also significantly higher in the neonate of these mothers table (3:1), (3:5), (3:6) and 
(3:7) figure (3:9) - (3:12) these findings are consistent with the previous report of 
WHO (1991); Dietz et al.; (1996) and Wesumperuma et al., (1999). They found 
that when the number of doses of TT vaccine increased from one to five, there was 
a corresponding increase the level of maternal and neonatal TT antibodies and in 
the duration of protection against tetanus. The newborn mother ratio of placental 
transfer is shown in table (3:6) and (3:7) figure (3:9), (3:10), (3:11) and (3:12). In 
contrast other studies have claimed that high levels of maternal antibodies impair 
placental transfer of IgG antibodies from the mothers to their neonates (Hood et al., 
1994 & De Moraes-Pinto et al., 1996). However measuring TT antibody level in 
umbilical cord or infant serum gives more accurate estimate of the baby’s neonatal 
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tetanus risk. Tetanus antibodies are mainly IgG class which is transported across 
the placenta, prefentally, in comparison to other isotypes. Therefore, the protective 
antibody level in the newborn is directly dependent on antibody level in maternal 
serum. This because IgG antibodies are pumped into the fetal side irrespective of 
maternal antibodies, due to the presence of specific receptor for IgG, thus allowing 
better protection of the infant than estimated from the maternal antibody level and 
newborn-maternal TT antibody ratio as shown in figure (3:9), (3:10) and (3:11) 
table (3:6) and (3:7). These finding are in agreement with Goncalves et al (1999) 
and Madico et al (1996). The minimal maternal antibody level of 0.1 IU/ml ensure 
protective antibody in infants, figure (3:7) table (3:1). The mother-fetus transport 
system require maturation, starting at 17th week (4 month) of gestation and 
gradually increases approximating maternal level by 33 week and some time 
reaching more than twice the maternal concentration at time of birth as depicted in 
newborns-maternal TT antibody ratio in table (3:6) and (3:7) figure (3:9), (3:10)
and (3:11). These results substantiate previous finding of Black et al (1980).    
The ratio between cord (newborn) and maternal level of IgG is retrospective 
and thus may represent the end product of various processes that have been 
operating over several weeks of pregnancy, for instant nutrition, placental size, 
genetic factor, infection as reported by Landor (1995). The difference in ratio 
between mothers and their newborns were not clinically significant, since some 
children still receive more than adequate protection as long as the mother has 
protective antibody levels. Table (3:6), (3:7) Figure (3:9), (3:10). 
In this study maternal age had a significant (P= 0.00) effect on newborn
maternal TT antibody ratio incontrast to previous study by Madico et al (1996) who 
showed no effect on newborn-maternal TT antibody ratios figure (3:9) table (3:6). 
Furthermore the study showed that full protection in age group 23-31 years old and 
the protective antibody level among age group of 32-40 years old minimal 
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protective level among and 14-22 years old. This could be explained by recent 
vaccination or booster vaccination in the first group.
However, discrepancies on the number of TT doses required to achieve 
protective immunity against neonatal tetanus during pregnancy and the duration of 
effective immunity remain unresolved (Koenig et al., 1998). Study also showed 
that women who receive 3-5 TT doses had high antibody level than those received 
1-2 TT doses table (3:2) and (3:4) and figure (3:6). This is consistent with Roy et al
(1992) who reported that tetanus immunity was dose dependent and the level and 
duration of immunity increased with increasing number of TT doses. However, this
finding showed clearly that women who were vaccinated with more than 5 TT 
doses had relatively lower TT antibody level (0.43 IU/ml) than those who had been 
vaccinated with 3-5 TT doses as shown in table (3:2). These findings are in 
agreement with previous findings of Aboud et al (2001) but the reduction of 
antibody levels in such women is not due to waning of antibody response as 
explained by Aboud et al (2001) but merely due to repetitive neutralizing
antibodies of the previously high antibody level by the vaccine. However, such 
women had memory that protects them against future infection. Nonetheless  in 
absence of previous immunization, a single dose of TT vaccine might provides 
little protection; however, one dose of TT given during pregnancy is beneficial if 
the interval between vaccine administration and delivery is at least 70 days 
(Galazka, 1998). This is in agreement with our findings as a single dose of tetanus 
vaccination during pregnancy was effective, since women who received one dose 
and women who received two doses of TT had comparable protection values in 
terms of IU/ml of TT antibody level table (3:2) figure (3:6). More over comparative 
measurement of antibody level in maternal and cord serum samples have
demonstrated that mother who received one or two doses of TT during pregnancy 
not only induced good protection but also specifically transfer higher levels of TT 
antibody to their newborns across the placenta table (3:4) and (3:7). This 
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substantiates previous report by Madico et al (1996) and Goncalves et al (1999). 
Furthermore, mother parity had significantly (P= 0.00) higher mean TT antibody 
level in multiparous women (1.28 IU/ ml) than in primiparous (0.28 IU/ ml) as 
shown in table (3:2) and figure (3:5). However, multiparous women had lower 
newborn/maternal TT antibody ratio (1.45) than did primiparous mother (1. 67) as 
shown in table (3:7) and figure (3:10). This might be due to the fact that 
multiparous women had received enough doses of TT vaccine. This is also in 
consistent with the finding of Deming et al (2002). However, incontrast De 
Morases-pinto et al (1998) reported that parity did not influence placental transfer 
of TT antibodies. 
Moreover, there was no significant differences between maternal TT 
antibodies of malaria infected mothers nor malaria non-infected mothers as 
depicted in table (3:4) and figure (3:8). However, placental malaria infection 
reduced placental transfer of TT antibody from infected mothers to their newborns 
to the level of 0.49 IU/ml compared to 1.56 IU/ml in newborn of malaria non-
infected mothers as shown in table (3:4) and figure (3:8). Newborn-maternal 
antibody ratio in malaria infected women was (0.59) whereas in malaria non-
infected women newborn-maternal TT antibody ratio was (1.64) which is 
statistically significant as shown in table (3:7) and figure (3:8) and (3:11).
This drop in newborn-maternal TT antibody ratio is probably due to 
pathological damages in the placenta that affect the FcR that ferry 
immunoglobulins across the placenta as reported by Bulmer et al (1993) and 
Galbraith et al (1980). In addition, Brown et al (2001) reported that repeated 
malaria infection that causes specific and/ or nonspecific stimulation of B-
lymphocytes in Gambian women in absence of active transplacental transfer of 
immunoglobulin into the featus. Recently DeMoraus-pinto et al (2005) reported 
that during malarial infection placental antibody transfer was reduced to 82% for S. 
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pneumonae and measles specific antibodies respectively. This clearly indicates that 
maternal immunity was generally reduced during malarial infection.
Furthermore, place of residence, ethnic group (tribal origin) have no effect 
on TT antibody level nor effect on N/M TT antibody ratio as shown in table (3:3) 
and (3:6), whereas the level of education has a significant (P= 0.01) effect on N/M 
TT antibody ratio which might be explained by number of TT vaccine doses 
received by each subgroup as shown in figure (3:3) and (3:4). 
All the deliveries in this study occurred in hospital setting under sterile
condition, no baby of the five non-vaccinated women or babies of women with low 
protection TT antibody level had the risk of contracting neonatal tetanus.
This study substantiate the WHO immunization schedule which is adequate 
and satisfactory to induce a protective TT antibody level but it needs to be 
intensified to reach all women of child-bearing age. Therefore WHO vaccination 
protocol was proved to be successful in this country, in Egypt (Kandil et al., 2004), 
Turky (Dundar et al., 2005) republic of South Africa (Idema, 2002) and Tanzania 
(Aboud et al., 2001).  
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CONCLUTION
1- ELISA is a useful technique to monitor protection against tetanus by 
quantitating TT antibody level in pregnant women and their neonate with 
view to evaluate their immune status and predict groups that require vaccine 
targeting in all women of childbearing age. 
2- Tetanus immunization during pregnancy produced effective and protective 
seroconversion and high protective TT antibody levels were obtained in all 
age groups and their newborn (0.1 – 1.0 IU/ml).
3- Comparative measurement of TT antibody in maternal and cord serum 
samples has demonstrated that mothers who received more than two doses of 
TT vaccine during pregnancy not only showed good protective TT antibody 
level but also specifically transfer higher level of TT antibody to their 
newborns across the placenta. Moreover maternal age and number of 
pregnancies independently had effect on newborn-maternal TT antibody 
ratio. 
4- Measuring tetanus antitoxin levels in umbilical cord gave a more accurate 
estimate of the baby’s neonatal tetanus risk.
5- The placental malaria infection seems to be linked to the low transplacental 
antibody transfer in this study.
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RECOMMENDATION
1- All women of childbearing age need to be more vigorsly vaccinated against 
tetanus.
2- To eliminate neonatal tetanus the health care system in Sudan must focus on 
effective tetanus immunization programme before and during pregnancy and 
may set a goal of vaccinating all women of childbearing age.
3- A better recording system on TT immunization is recommended to avoid 
hyper-immunization of pregnant women and to optimize the cost-
effectiveness of the immunization programme. 
4- ELISA technique must be implemented to monitor the target population to 
detect their immune status and predict groups that require vaccine targeting 
to ensure complete coverage of TT immunization especially in rural area and 
around shanty town and to give women of childbearing age not less than two 
and not more than five doses of TT vaccine. However in urban area most 
individuals have been immunized with TT during childhood, women may 
need only one dose of TT vaccine during each pregnancy. 
5- Clean hygienic delivery conditions should be observed in rural areas.
6- In future studies it may be important to determine antitetanus IgG subclasses 
as asole marker to predict protection in the fetus especially in low 
socioeconomic groups.    
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